UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-K
[X]
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR
THE FISCAL YEAR ENDED DECEMBER 31, 2019
OR
[ ]
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR
THE TRANSITION PERIOD FROM ____ TO _______
Commission
File Number: 000-54286
SURNA
INC.
(Exact
name of registrant as specified in its charter)
Nevada |
|
27-3911608 |
(State
or other jurisdiction of
incorporation
or organization)
|
|
(I.R.S.
Employer
Identification
No.)
|
1780
55th Street, Boulder, Colorado |
|
80301 |
(Address
of principal executive offices) |
|
(Zip
code) |
(303)
993-5271
(Registrant’s
telephone number, including area code)
Securities
registered pursuant to Section 12(b) of the Exchange
Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
N/A |
|
N/A |
|
N/A |
Securities
registered pursuant to Section 12(g) of the Act:
Title
of Each Class Registered
Common
stock, par value $0.00001 per share
Indicate
by check mark if the registrant is a well-known seasoned issuer, as
defined in Rule 405 of the Securities Act. Yes [ ] No
[X].
Indicate
by check mark if the registrant is not required to file reports
pursuant to Section 13 or Section 15(d) of the Act. Yes
[ ] No [X].
Indicate
by check mark whether the issuer (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Exchange Act during the
preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to
such filing requirements for the last 90 days. Yes [X] No
[ ].
Indicate
by check mark whether the registrant has submitted electronically
every Interactive Data File required to be submitted pursuant to
Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant
was required to submit such files). Yes [X] No
[ ].
Indicate
by check mark whether the registrant is a large accelerated filer,
an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of
“large accelerated filer, “accelerated filer,” “non-accelerated
filer,” “smaller reporting company,” and “emerging growth company”
in Rule 12b-2 of the Exchange Act.
Large
Accelerated Filer |
[ ] |
Accelerated
Filer |
[ ] |
Non-accelerated
Filer |
[ ] |
Smaller
Reporting Company |
[X] |
|
Emerging
Growth Company |
[ ] |
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
[ ]
Indicate
by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Exchange Act). Yes [ ] No
[X].
The
aggregate market value of the voting and non-voting common stock
held by non-affiliates of the registrant as of the last business
day of the registrant’s most recently completed second fiscal
quarter was approximately $8,757,000 based upon a closing price of
$0.039 reported for such date on the OTCMarkets.
As of
March 23, 2020, the number of outstanding shares of common stock of
the registrant was 236,526,638.
DOCUMENTS
INCORPORATED BY REFERENCE
None.
Surna
Inc.
Annual
Report on Form 10-K
For
Fiscal Year Ended December 31, 2019
Table
of Contents
In this Annual Report, unless otherwise indicated, the “Company”,
“we”, “us” or “our” refer to Surna Inc. and, where appropriate, its
wholly-owned subsidiary.
Hemp and marijuana are technically both part of the “Cannabis
sativa L.” plant. “Hemp” is a term used to classify varieties of
cannabis that contain 0.3% or less tetrahydrocannabinol (“THC”)
content (by dry weight), the principal psychoactive constituent of
cannabis. Hemp and its derivatives were federally legalized in the
United States as part the Agricultural Act of 2018. “Marijuana” is
a term used to classify varieties of cannabis that contain more
than 0.3% THC (by dry weight). Marijuana is not federally legal in
the United States. Many states, however, have taken action to make
marijuana legal for all purposes, made it available for medical
uses, decriminalized it or a combination thereof. We currently
provide nearly all of our products and services to customers that
cultivate marijuana. In this Annual Report, unless otherwise
indicated, “cannabis” refers to “marijuana.”
CAUTIONARY
STATEMENT
This
Annual Report on Form 10-K, including “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” in Item
7, contains forward-looking statements that involve substantial
risks and uncertainties. These forward-looking statements are not
historical facts, but are based on current management expectations
that involve substantial risks, uncertainties, and other factors,
some of which are beyond our control and difficult to predict and
could cause actual results to differ materially from those
expressed in, or implied by, these forward-looking statements.
Forward-looking statements relate to future events or our future
financial performance. We generally identify forward-looking
statements by terminology such as “may,” “will,” “should,”
“expects,” “plans,” “anticipates,” “could,” “intends,” “target,”
“projects,” “contemplates,” “believes,” “estimates,” “predicts,”
“potential” or “continue” or the negative of these terms or other
similar words. All statements, other than statements of historical
fact, are statements that could be deemed forward-looking
statements including, but not limited to, any projections of
revenue, gross profit, earnings or loss, tax provisions, cash flows
or other financial items; any statements of the plans, strategies
or objectives of management for future operations; any statements
regarding current or future macroeconomic or industry-specific
trends or events and the impact of those trends and events on us or
our financial performance; any statements regarding pending
investigations, legal claims or tax disputes; any statements of
expectation or belief; and any statements of assumptions underlying
any of the foregoing.
These
forward-looking statements are subject to known and unknown risks,
uncertainties, assumptions and other factors that could cause our
actual results of operations, financial condition, liquidity,
performance, prospects, opportunities, achievements or industry
results, as well as those of the markets we serve or intend to
serve, to differ materially from those expressed in, or suggested
by, these forward-looking statements. These forward-looking
statements are based on assumptions regarding our present and
future business strategies and the environment in which we operate.
Important factors that could cause those differences include, but
are not limited to:
|
● |
our
business prospects and the prospects of our existing and
prospective customers; |
|
● |
the
inherent uncertainty of product development; |
|
● |
regulatory,
legislative and judicial developments, especially those related to
changes in, and the enforcement of, cannabis laws; |
|
● |
increasing
competitive pressures in our industry; |
|
● |
the ability to
effectively operate our business, including servicing our existing
customers and obtaining new business, as a result of our recent
workforce reduction; |
|
● |
our
relationships with our customers and suppliers; |
|
● |
the
continuation of normal payment terms and conditions with our
customers and suppliers, including our ability to obtain advance
payments from our customers; |
|
● |
general economic conditions, our customers’ operations and access
to capital, and market and business disruptions including severe
weather conditions, natural disasters, health hazards, terrorist
activities, financial crises, political crises or other major
events, or the prospect of these events, adversely affecting demand
for the products and services offered by us in the markets in which
we operate; |
|
● |
changes
in our business strategy or development plans, including our
expected level of capital expenses and working capital; |
|
● |
our
ability to attract and retain qualified personnel; |
|
● |
our
ability to raise equity and debt capital to fund our operations and
growth strategy, including possible acquisitions; |
|
● |
our
ability to identify, complete and integrate potential strategic
acquisitions; |
|
● |
future
revenue being lower than expected; |
|
● |
our
ability to convert our backlog into revenue in a timely manner, or
at all; and |
|
● |
our
intention not to pay dividends. |
Although
we believe that the assumptions on which these forward-looking
statements are based are reasonable, any of those assumptions could
prove to be inaccurate, and as a result, the forward-looking
statements based on those assumptions also could be inaccurate. In
light of these and other uncertainties, the inclusion of a
projection or forward-looking statement in this annual report on
Form 10-K should not be regarded as a representation by us that our
plans and objectives will be achieved. These risks and
uncertainties include those described or identified in “Risk
Factors” in this Annual Report on Form 10-K. You should not place
undue reliance on these forward-looking statements, which apply
only as of the date of this Annual Report on Form 10-K. Except as
required by the federal securities laws, we undertake no obligation
to revise or update any forward-looking statements, whether as a
result of new information, future events or otherwise, to reflect
events or circumstances occurring after the date of this Annual
Report on Form 10-K. The forward-looking statements and projections
contained in this Annual Report on Form 10-K are excluded from the
safe harbor protection provided by Section 27A of the Securities
Act.
Non-GAAP Financial Measures
To
supplement our financial results on U.S. generally accepted
accounting principles (“GAAP”) basis, we use non-GAAP measures
including net bookings, backlog, as well as adjusted net income
(loss) which reflects adjustments for certain non-cash expenses
such as stock-based compensation, certain debt-related items and
depreciation expense. We believe these non-GAAP measures are
helpful in understanding our past performance and are intended to
aid in evaluating our potential future results. The presentation of
these non-GAAP measures should be considered in addition to our
GAAP results and are not intended to be considered in isolation or
as a substitute for financial information prepared or presented in
accordance with GAAP. We believe these non-GAAP financial measures
reflect an additional way to view aspects of our operations that,
when viewed with our GAAP results, provide a more complete
understanding of factors and trends affecting our business. For
purposes of this Annual Report, (i) “adjusted net income (loss)”
and “adjusted operating income (loss)” mean GAAP net income (loss)
and operating income (loss), respectively, after adjustment for
non-cash equity compensation expense, debt-related items and
depreciation expense, and (ii) “net bookings” means new sales
contracts executed during the quarter for which we received an
initial deposit, net of any adjustments including cancelations and
change orders during the quarter.
Our
backlog, remaining performance obligations and net bookings may not
be indicative of future operating results, and our customers may
attempt to renegotiate or terminate their contracts for a number of
reasons, including delays in or inability to obtain project
financing or licensing or abandonment of the project entirely.
Accordingly, there can be no assurance that contracts included in
the backlog or remaining performance obligations will actually
generate revenues or when the actual revenues will be
generated.
PART I
Item 1. Business
Overview
We
design, engineer and sell cultivation technologies for controlled
environment agriculture including: (i) liquid-based process cooling
systems and other climate control systems, (ii) air handling
equipment and systems, (iii) a full-service engineering package for
designing and engineering commercial scale thermodynamic systems
specific to cannabis cultivation facilities, and (iv) automation
and control devices, systems and technologies used for
environmental, lighting and climate control. Our customers include
commercial, state- and provincial-regulated cannabis growers in the
U.S. and Canada as well as other international locations, including
those growers building new facilities and those expanding or
retrofitting existing facilities. Currently, our revenue stream is
derived primarily from supplying our products, services and
technologies to commercial indoor and hybrid sealed greenhouse
facilities ranging from several thousand to more than 100,000
square feet.
Headquartered
in Boulder, Colorado, we leverage our experience in this space to
bring value-added climate control solutions to our customers that
help improve their overall crop quality and yield, optimize energy
and water efficiency, and satisfy the evolving state and local
codes, permitting and regulatory requirements. Although our
customers do, we neither produce nor sell cannabis.
Indoor
cannabis cultivators are facing multiple headwinds of high energy
costs, increasingly rigorous quality standards and declining
cannabis prices. To be competitive, among other things, our
customers must develop innovative ways to meet the demands of their
business and reduce energy costs, 90% of which is typically related
to their HVAC (50%) and lighting systems (40%). HVAC systems have
historically been our focus. We often have the advantage of early
engagement with our customers at the pre-build and construction
phases and the corresponding opportunity to build longer-term
relationships with our existing customers and their facilities.
Going forward, our plan is to leverage our existing customer
relationships and attempt to sell them additional products and
services, thereby becoming “stickier” to our customers, in an
effort to generate incremental revenue.
We
have three core assets that we believe are important to our going
forward business strategy. First, we have multi-year relationships
with customers and others in the cannabis industry. Second, we have
specialized engineering know-how and experience gathered from
designing environmental control systems for cannabis cultivation
facilities since 2016. Third, we have a line of proprietary
environmental control products, which we are in the process of
expanding.
We
are an integrated provider of mechanical engineering design,
proprietary environmental control equipment and a controls and
automation offering serving the cannabis space. We believe our
employees have more experience than most other mechanical
engineering firms serving this industry. Our customers engage us
for their environmental and climate control systems because they
want experts to design their facilities, and they come to us
because of our reputation. We leverage our reputation and know-how
against the many local contractors and mechanical engineers who
collectively constitute our largest competitors.
A number of recent events have had an adverse impact on our
operations and financial condition, including constraints on
capital availability for our customers and prospects who have
commenced, or are contemplating, new and expanded cannabis
cultivation facilities and the recent outbreak of COVID-19, a novel
strain of coronavirus first identified in China, which has spread
across the globe including the U.S. Most recently, the response to
this coronavirus by federal, state and local governments in the
U.S. has resulted in significant market and business disruptions
across many industries and affecting businesses of all sizes. This
pandemic has also caused significant stock market volatility and
further tightened capital access for most businesses.
As a result of these events, we assessed our near-term operations,
working capital, finances and capital formation opportunities, and
implemented, in late March 2020, a downsizing of our operations,
including workforce reductions, reductions of salaried employee
compensation and a reduction of hours worked to preserve cash
resources, cut costs and focus our operations on customer-centric
sales and project management activities. In addition, any potential
government mandate to limit non-essential work would have a
material adverse effect on management’s revised plans. The extent
to which COVID-19 will impact our business and financial results
will depend on future developments, which are uncertain and cannot
be predicted at this time.
The duration and likelihood of success of our downsizing effort,
workforce reduction and cost-cutting measures are uncertain. If
these actions do not meet our expectations, or additional capital
is not available, we may not be able to continue our operations.
Other factors that will affect our ability to continue operations
include the market demand for our products and services, our
ability to service the needs of our customers and prospects with a
reduced workforce, potential contract cancellations, project scope
reductions and project delays, our ability to fulfill our current
backlog, management of our working capital, the availability of
cash to fund our operations, and the continuation of normal payment
terms and conditions for purchase of our products. Due to the
heightened uncertainty relating to the potential impacts of the
coronavirus on our business operations, we believe our cash
balances and cash flow from operations will be insufficient to fund
our operations for the next twelve months. If our customers or
prospects are unable to obtain project financing and we are unable
to increase revenues, or otherwise generate cash flows from
operations, we will not be able to successfully execute on the
various strategies and initiatives we have set forth in this Annual
Report to grow our business.
Shares
of our common stock are traded on The OTC Markets under the ticker
symbol “SRNA.”
Our
Growth Strategy
We
believe there are fundamentally three ways to grow a business: (i)
increase the number of customers, (ii) increase the average revenue
per order, or (iii) increase the frequency of orders. Our growth
strategy is threefold:
|
1. |
Sell
proverbial “Chevys.” In addition to “Cadillac” -level products,
sell “Chevy” or equivalent products to satisfy a wider range of
points along the demand curve. Anticipated result: Increase the
number of customers. |
We
have a sales and marketing program that generates many prospective
customer relationships. However, our limited range of higher cost
products, mostly chilled water systems, reduces the number of
customer prospects who can afford to buy from us. We will broaden
our product line to include lower- and mid-cost products, such as
split systems and packaged roof top units, as well as other
technology solutions, so that a broader group of growers can take
advantage of our engineering expertise and capabilities. We believe
these new products and services will increase our addressable
market and increase sales, further leveraging our investment in
sales and marketing.
|
2. |
Sell
proverbial “steering wheels.” Sell our customers the automated
facilities control systems they need—directly. Anticipated result:
Increase average order size. |
Growing
live plants indoors in a controlled environment is a technically
demanding business, and a failed crop can cost a grower significant
foregone revenue. We believe our licensed professional engineers
are some of the industry’s leading experts in the design of such
facilities, and we seek to extend that leadership into more
advanced technology products.
Last
year we introduced our SentryIQ™ control system. If our climate
control design and products are the proverbial car, then SentryIQ™
is the proverbial steering wheel—one is needed to direct the car
where to go. Before SentryIQ™, we had to send our customers
elsewhere for controls to regulate their cultivation environments,
but we now have the ability to capture that revenue.
Our
next step down this technology and innovation road will be the
eventual development of the equivalent of a self-driving car.
Growers will tell the control system what they want to achieve, and
the system will sense the environment and direct the climate
control system to achieve the grower’s goals. These systems will be
able to integrate data analytics—and eventually deploy artificial
intelligence—to optimize multiple variables to maximize the
grower’s profits. While we are in the early stages of development
of these technology-driven systems, we believe it is important for
us to become a player in this market because it expands our
addressable market for both sensors and software while offering the
possibility of higher margins and recurring revenue over
time.
|
3. |
Add
more proverbial “dealers.” Engage in one or more strategic
relationships with other technology leaders that serve our
industry. Anticipated result: Increase the number of
customers. |
Such
relationships might include referral marketing agreements,
co-development of unique integrated solutions with best-in-class
partners, and acquisitions. To extend the automotive analogy,
engaging in these types of relationships is like adding more
dealers to sell our products, at little cost to us.
********
Our
Key Initiatives
Our
goal for the immediate future is to grow organically, strategically
and profitably. We believe the worldwide market for indoor-grown
cannabis products will grow substantially for the foreseeable
future, and we hope this will lead to more new build projects to
drive our continued growth. Here are some of the initiatives we
pursued in 2019, and where more work is needed to progress each of
these initiatives.
Focus on Multi-facility Operators. In 2019, in addition to
independent smaller growers, we actively pursued business from
multi-facility operators (MFOs), which we define as businesses that
own and operate two or more cannabis cultivation facilities in
either the U.S. or Canada. These MFOs are typically larger and have
greater financial and organizational wherewithal to buy more and
larger systems and are less prone to project delays and
cancellations, compared to the smaller (and riskier) independent
cultivators that had been our primary customers in the past. We
enjoyed success in this effort, booking seven projects with MFOs,
representing $8.3 million in revenue, or 55% of our total 2019
revenue. However, three of these projects, generating a total of
$6.7 million in revenue, were with a single MFO. Going forward, we
will conduct our operations to seek a sales pipeline with MFO
customers that we believe will result in more consistent and
predictable revenue and cash flow. Because MFOs are typically more
sophisticated and may, in many cases, have in-house engineering
teams, such MFOs may not need the expertise and experience we
offer. This contrasts with the independent smaller grower market
that places significant value in our cannabis-specific expertise
and experience and continues to represent an important market
segment for us.
The
table below shows our 2019 full year results for commercial-scale
projects, which we define as contracts with a value over $100,000,
by project and customer type.

To
achieve profitability in the future, we must first be able to
generate a more consistent and predictable revenue stream. To do
so, we must: (i) maximize our new build facility projects, and (ii)
supplement those projects with an increased number of retrofit and
expansion projects—which typically have shorter completion cycles
and fewer external contingencies that we do not control.
Historically, whenever a new build project has been delayed or
cancelled, which can occur often, our revenue and cash flow has
taken a corresponding dramatic hit.
Offer a Broader Range of Products and Services Across the
Cultivation Facility Lifecycle. During 2019, we
fulfilled the first step of this goal with the introduction of our
SentryIQ™ controls package. We also began offering full mechanical,
electrical, and plumbing engineering services, developed and sold a
four-pipe environmental control system with Surna branded fan coil
units and custom air handlers, developed a proprietary
destratification fan, and performed facility retrofit services. Our
new custom air handlers alone generated $2.3 million in revenue in
2019.
Following
up on our product launch successes in 2019, we plan to address
facility lifecycle revenue opportunities by leveraging our strong
brand name and positioning ourselves as the “trusted advisor” in
environmental controls management. Our expanded product offering is
illustrated by the following 4-phase matrix of product/service
depth and facility lifecycle participation.
Our
plan is to attempt to become
“stickier” to our customers by providing climate control products
and services across the entire 4-phase facility lifecycle. Each
phase of the facility lifecycle has many activities that present
potential opportunities for us, some of which we will pursue. We do
not intend to offer products and services in all activities in each
phase, but rather we will focus on technology and innovation that
provide value-add to our customers as they attempt to seek out
“best-in-class” partners to automate and control the indoor grow
facilities of the future. We believe, if successful, this could
possibly translate into greater demand for our proprietary,
customized equipment, technology and software solutions.
Enter Strategic Alliances to Expand our Marketing and Sales
Reach. Although we explored a few acquisitions and
strategic alliance opportunities in 2019, we did not attract
partners of the caliber or business segment that we are seeking. We
have identified several business verticals that we believe are
logical and natural complements to our climate control business,
such as: lighting, fertigation (automated process of delivering
nutrients and water to plants), benches (customized systems to
optimize use of the growing space), cultivation management
technology (software), consumables (growing, packaging, facility
and lab supplies), and operational improvement analytics (modeling,
data aggregation and artificial intelligence). We also believe we
should consider strategic alliances, such as distribution,
reseller, co-marketing or product development agreements, with
select companies which are consistent with our strategic direction.
Our strategic alliances will likely involve development of more
comprehensive, end-to-end, integrated solutions for our customers,
as well as specialized products and services that help cultivators
compete in the market, whether through automation, software or
operating efficiencies.

If
some of these strategic alliances are successful in driving
top-line revenue for us and our partners, over time these
relationships could develop into more exclusive arrangements or
evolve into possible acquisitions or a source of strategic capital
for us. There can be no assurance that we will be able to
successfully execute any of these strategic initiatives. Efforts
will be primarily focused on working with new strategic partners to
co-market each other’s products and services and possibly jointly
develop new and improved products and services with
cannabis-specific applications, as opposed to exclusively seeking
acquisitions.
Cash and Dilution. We started 2019 with just over $250,000
in cash but, with a new discipline on cost control and strong
revenue growth, we were able to increase our cash to $922,000 at
the end of 2019. We were self-sustaining during 2019, having used
operating cash flows to support our operations, and we did not
require any outside capital. By contrast, in 2017 and 2018, we
experienced losses and cash flow deficits that had to be financed
with a series of dilutive capital raises. In 2019, we exercised
strict financial discipline to achieve the goal of cash operating
profitability and cash flow sustainability—in part of sheer
necessity, and in part to simply validate that we had a financially
viable business model. We believe we do, with our first two
profitable quarters ever in both the second and third quarter of
2019, and adjusted net income in 2019 of $92,000 compared to an
adjusted net loss in 2018 of $2,592,000. Our adjusted net income
(loss) is our GAAP net income (loss) after addback for our non-cash
equity compensation expenses, debt-related items and depreciation
expense.
Though
improved in 2019, our working capital remains negative, which is a
constant impediment to the overall viability of our business as
planned, so we must land more MFO and other contracts and we may
have to raise capital again to fund our working capital need and
future growth. As discussed above, due to the heightened
uncertainty relating to the potential impacts of the coronavirus on
our business operations, we implemented a workforce reduction in
late March 2020 to preserve cash resources and focus our operations
on customer-centric sales and project management activities. We do
not know the duration or the likelihood of success of this
downsizing effort. However, if our customers and customer prospects
are unable to obtain project financing and we are unable to
increase revenues, we may not be able to continue our
operations.
Investor Relations. We previously had limited investor
relations activities of any kind prior to 2019. Now, we have a
clear plan designed to create an actively traded, widely held, and
fully valued stock over time—and in concert with our achievement of
consistent financial goals. In 2019 we took the required initial
steps of hosting regular earnings calls and attending a select
number of investor conferences.
Products
and Services
We
now offer a deeper range of products and services than the
mechanical engineering and modular chilled water systems we
historically offered. This includes products and services targeting
smaller indoor grow facilities and commercial-scale facilities as
well as sealed greenhouse, or hybrid, facilities.
Services: Engineering and Design. Previously, we provided
basic engineering and design work. Currently, we believe we have
leading edge, sophisticated engineering capabilities which we
attempt to leverage with independent small growers as well as MFOs
that are building larger and more sophisticated commercial
projects. As evidenced by our 2019 success penetrating the MFO
market, our reputation today reflects this reality.
Going
forward, we will: (i) emphasize our strong mechanical engineering
team that includes an in-house staff of degreed engineers including
an experienced licensed professional engineer (PE), (ii) offer
pre-construction energy modeling to help our customers and enhance
our sales closing rate, (iii) develop an engineering, design and
audit services program for the expanding retrofit market, which
remediates existing grow facilities that suffer from sub-optimal
performance, and (iv) potentially offer other facility management
programs.
Our
technical experience and know-how in designing indoor cannabis
cultivation facilities allow us to deliver to our customers
practical solutions to complicated problems in three primary areas:
(i) precision climate and environmental controls, (ii) energy and
water efficiency, and (iii) building code and permitting. Our
engineering design typically includes all mechanical components of
a climate control system: cooling and heating, dehumidification,
ventilation, air sanitation and odor control. We provide load
calculations, equipment specifications, and engineered systems
drawings for both the cultivation and comfort cooling portions of
our customers’ facilities. We also have experience in, or knowledge
of, state and local permitting and code compliance for cannabis
facilities in states and provinces where cannabis has been
legalized for either recreational or medical use or is expected to
be legalized, and we provide stamped, engineered drawings in all
states and provinces where we operate.
Our
competitive advantages are our experience and reputation. Since
2006, we have been continuously improving our facility designs
which we believe distinguishes us from our competition, including
local heating, ventilation and air conditioning (“HVAC”)
contractors, traditional HVAC design consultants, and others who
may lack our cannabis-specific expertise. Indoor sealed grow
facilities present a very difficult mechanical engineering
challenge, and traditional mechanical engineers, without our
cannabis experience, are typically unfamiliar with the precise
climate and air control requirements needed for such facilities. As
important, they may be unable to effectively navigate the local
code and permitting rules which did not contemplate cannabis
cultivation facilities when enacted. With our engineering design
resources and experience, we are able to provide a code-compliant
mechanical plan set in any state or province by collaborating with
local regulators and our customers to engineer creative solutions
that not only meet the intent of the local codes but also address
concerns about the growing energy and resource usage of these
facilities.
Energy
use is, and will increasingly become, a primary concern for
regulators and indoor cultivators. Two states, Massachusetts and
Illinois, have already placed regulatory caps on energy density in
cannabis cultivation facilities and we expect this trend to
continue. Energy costs are frequently the second largest operating
expense for a cultivation facility, after labor, with HVAC and
lighting comprising approximately 50% and 40%, respectively, of a
facility’s energy use.
As a
result, licensed producers are adopting practices to maximize
energy efficiency and thereby reduce operating costs, which will
become even more important as the industry matures and wholesale
prices continue to decline. These practices include more efficient
uses of water, more efficient lighting (typically LED lighting),
and renewable energy alternatives. Sealed greenhouses, or hybrid
facilities—which are insulated for energy efficiency and combine
natural light with the use of artificial lights—also provide a more
economical way to grow cannabis compared to warehouse type indoor
production. But regardless of whether an indoor or a hybrid
facility is the grow venue, precise environmental controls are
required to deliver consistent product quality and yield. We are
evaluating possible strategic relationships with providers that are
seeking an environmental controls partner for these specific
facility applications.
We
believe the right solution for our cultivation customers must
include: (i) precise temperature/humidity control; (ii) reduced
fungus, pollen, pesticide and insect contamination risk
(“bio-security”); (iii) controlled regulatory compliance risk; and
(iv) lower maintenance complexity, costs and downtime.
Our
bio-security program uses a combination of a sealed facility and
customized approaches to air sterilization to maintain facility
standards, while destroying harmful airborne microbes without the
production of byproducts. Additionally, our ductless modular
chilled water systems—using fan coil units within each grow
room—isolate the air and potential contaminants within each room,
while taking advantage of the energy efficiencies and redundancies
offered by such systems. Our experience has shown that our
precision environmental controls can reduce the reliance on the use
of harmful pesticides and fungicides. We also believe our
experience in the tightly regulated Canadian market where
pharmaceutical-like standards (including Good Manufacturing
Practice standards) exist for filtration, air quality and
post-harvest plant quality gives us an advantage over our
competitors, especially as product quality testing regulations
continue to be enacted and made more stringent by state, provincial
and local agencies.
The
following perspectives explain and help conceptualize the
complexity of the environmental controls systems that need to be
deployed by indoor cultivators:
|
● |
Lighting.
Lighting demand is 70 times more energy intensive than commercial
office buildings. This lighting intensity creates heat, which when
combined with plant transpiration to create humidity, creates the
need for dehumidification and corresponding additional energy
demand. Further complicating matters, lighting schedules and
density must be adjusted for the clone, vegetative and flowering
stages of cannabis cultivation, and associated variances in
watering rates and temperature and humidity targets. |
|
|
|
|
● |
HVAC.
HVAC energy use is driven by the need to remove the heat emitted
from lighting and the moisture released during the plant’s
evapotranspiration process, coupled with air circulation and odor
and contaminant filtration requirements. |
|
|
|
|
● |
Legacy
Systems. Mechanical systems are often designed and/or installed
poorly, which can increase energy consumption and inconsistencies
in environmental conditions. Reasons include: (i) cultivators
deploying HVAC systems without an understanding of how the HVAC
system impacts the growing environment, (ii) cultivators failing to
understand the criticality of proper installation, commissioning
and servicing of the equipment, even if properly designed, (iii)
HVAC systems selected without understanding the interrelationship
between sensible (cooling) and latent (moisture) factors, and (iv)
most HVAC systems are designed for human occupied spaces, not
process loads to accommodate plants. |
New
technologies and applications, coupled with emerging cultivation
innovations, are providing opportunities for increased efficiency,
which we are positioned to deliver to our customers. Our
engineering and product development teams, which currently consist
of nine people, are fully qualified and committed to delivering
energy and resource efficient solutions to commercial cultivators.
Leveraging their technical competence, and our customers’
increasing focus on energy efficiency, quality and yield, in the
future we intend to offer retrofit/design, energy audit, energy
efficiency improvement, and performance audit services.
Products: Environmental Control Systems.
Previously,
we exclusively sold modular chilled water systems. In the future,
we intend to expand our product offering to include other HVAC
solutions, such as custom air handling units, split systems,
packaged roof-top units, self-contained and complex water chilled
systems. During 2019, we launched upgraded equipment lines of fan
coils and air handlers. This expanded product line will allow us in
the future to offer less expensive products that can help us serve
customers who are more cost sensitive.
We are now
offering various configurations of our new Surna-branded fan coil
units, which provide greater efficiency, design flexibility and
control for growers using modular chilled water systems. During
2019, we delivered our first custom-designed ducted air handling
system, which is another alternative to our new and improved
ductless fan coil units.
We are
capable of offering a utility rebate consulting service to help our
new build customers obtain utility rebates. While this service is
not expected to generate significant revenue, it should help us
sell our environmental controls systems because our customers will
be able to use these rebates to offset some of their capital
costs.
There can
be no assurance that we will be able to successfully execute any of
these product initiatives, or identify, test and develop improved
products or services, or that such products or services will
generate revenue or profitability at the levels we expect. We also
intend to work with select “best-in-class” vendors and partners
that may be interested in jointly developing and marketing new and
improved products and services with cannabis-specific
applications.
Technology:
Sensors, Controls and Automation Business. One of our key
initiatives for 2019 was the development of a branded, proprietary
controls and monitoring offering (consisting of sensors,
controllers, software, monitoring and a user interface). We
accomplished this and launched in April 2019 our
SentryIQTM sensors, controls and automation (“SCA”)
platform—a turnkey, single-vendor HVAC equipment and controls
integration solution to new build projects as well as existing
facilities in the startup and operation phases. We have now entered
into seven contracts with six different companies to implement our
SentryIQTM SCA platform covering a combined total of
over 212,000 square feet of cultivation space. This product line is
important for tactical and strategic reasons, and we hope to offer
this as a standalone offering in the future.
Cultivation
facilities must have SCA to operate their HVAC equipment. In simple
form, SCA is the thermostat in the room, with the occupant
selecting the desired temperature set point, the wall thermostat
(Sensor) detecting the actual temperature, and when the space
temperature deviates from the desired set point the thermostat
(Control) commands the furnace or air-conditioner to supply heated
or cooled air to bring the room temperature back to the set point.
In the case of the cultivation facilities that we serve, there are
more environmental conditions to monitor and control (such as
temperature, relative humidity, CO2, lighting, vapor
pressure deficit status, and more) than in a typical residential
home.
Indoor
cannabis growers also need to vary and tightly control
environmental conditions depending on the stage of plant growth
(i.e., clone, vegetative and flowering stages of cannabis
cultivation), the time of day, and the plant genetics. In a
cultivation facility the desired conditions change many times
during the plant’s growth cycle and even within a day, and this is
most easily accomplished with a programmable environmental control
system (Automation), not unlike a simple programmable thermostat in
a home.
Our
SentryIQTM SCA package includes precision sensors to
measure temperature, humidity, and CO2 levels—more
accurately than typical HVAC sensors and within tighter tolerance
levels. Our controllers are purpose-built computers programmed by
us to ensure our industrial environmental control equipment follows
the engineered sequences of operation to obtain desired setpoints.
Our sensors connect to our branded controllers through wires
installed in the facility, and similarly they are wired to our HVAC
equipment (e.g., chillers, fan coils and dehumidifiers) to direct
these pieces of equipment. The controllers also provide a user
interface on a screen so that they can be easily programmed and
controlled to achieve the customer’s environmental objectives, and
also giving the cultivator the ability to access this data and
react to alerts remotely.
We
have entered this business to satisfy our customer’s needs that we
did not previously address and that historically was provided by
third-party controls contractors. Our entry into the SCA market
helps both our customers’ and our business. Our customers benefit
because they are saved the extra work of finding and engaging a
controls contractor, which allows them to get their facility up and
running more quickly by taking one decision off the table and
thereby establishing a single point of responsibility for controls
implementation. We are also in a position to provide SCA because we
know our proprietary equipment better than anyone, thereby ensuring
smooth integration with our equipment with no work scope
shortcomings, what we refer to as “scope gap.”
From
a tactical perspective, with limited incremental selling costs, our
current sales team can now offer our SCA package to nearly every
prospect since every cultivation facility should have SCA
technology. We believe this technology value-added solution gives
us an opportunity to achieve incremental project revenue.
Strategically, through our SCA package, we are also able to deepen
our ongoing relationship with the customer which positions us for a
long-term customer relationship by tethering us to the customer
through a controls interface (dashboard) to their facility and,
eventually, allow our customer to use artificial intelligence (AI)
by aggregating environment and growing data to optimize energy use,
operating efficiency, and product quality and yield. While there
are several other total controls systems providers, we believe that
our industry know-how, experience and reputation with climate
control equipment may give us a compelling and competitive SCA
offering.
Sales
and Marketing
Multi-Facility Operator Focus
We
plan to have our sales and marketing efforts include a focus on
MFOs. However, we face multiple sources of competition in our
attempt to penetrate the MFO market.
|
● |
First,
some companies with multiple cultivation facilities have internal
staffs with the requisite expertise to manage their environmental
control needs, and who are able to access and engage vendors for
both engineering services and equipment without external
help. |
|
|
|
|
● |
Second,
some large, multi-state and multi-national engineering and
construction firms, which have deep engineering and construction
management experience and expertise, have entered this
market. |
|
|
|
|
● |
Third,
we compete with other cannabis-focused service providers, that like
us promote their industry expertise and experience. |
|
|
|
|
● |
Fourth,
several larger, brand name HVAC equipment manufacturers are now
pursuing the cannabis cultivation market directly through their own
sales forces. |
We
believe we can compete in the MFO market for the following
reasons:
|
● |
We
are one of the oldest and most experienced specialty engineering
firms serving the indoor cannabis cultivation market, and we
believe that MFOs will value the expertise we have gained from
designing environmental control systems for cannabis cultivation
facilities since 2016. |
|
|
|
|
● |
Unlike
the local and regional engineering firms operating in the market,
we have the capability and experience to perform work across the
U.S. and Canada, thereby matching the facilities footprint of our
MFO prospects. |
|
|
|
|
● |
We
believe that the MFOs value the range of experience and expertise
that our personnel provide. Our professional staff has expertise
covering the gamut, including commercial agriculture, engineering
and facility design, HVAC technology, applications and controls,
energy efficiency, and sustainability. |
|
|
|
|
● |
We
have deep networks with cannabis cultivators, HVAC technical
experts, AgTech experts, sustainability leaders, and agricultural
resources that we can easily access and bring to bear for the
benefit of our customers. |
|
|
|
|
● |
And
finally, our 2019 business with four MFOs, covering a total of
seven projects with an average contract value of $1.4 million,
provides important validation and enhances our credibility in the
eyes of other MFOs that we are pursuing. |
Our
ability to develop relationships with, and obtain new business
from, other MFOs will be critical to generating consistent revenues
quarter-over-quarter. During the second half of 2019, we believe
certain Canadian MFOs delayed new or expansion projects as access
to capital had tightened due to market conditions in that country.
Notwithstanding our efforts, there is no assurance that we will be
successful in growing and maintaining our business with these MFOs,
especially in light of the uncertainty surrounding the potential
impact of the coronavirus on our business and the business of our
customers and customer prospects.
New
Commercial-Scale Projects Driven by Cannabis
Legalization
The
demand for our environmental control systems is driven primarily by
the construction of new cannabis cultivation facilities in the U.S.
and Canada. New construction activity is, in turn, driven by state
legislation approving either medical or recreational cannabis use.
Recent regulatory changes involving medical and/or recreational
cannabis use in various jurisdictions, such as California,
Michigan, Oklahoma, Utah, Missouri, Illinois and Canada, tend to be
a leading indicator for the granting of licenses for new facility
construction. As more new cultivation facilities become licensed,
we in turn have an expanded set of potential customers that might
buy our environmental control systems. However, since both medical
and recreational cannabis use remains prohibited under U.S. federal
law, uncertainty continues and tends to unfavorably impact the
development and financing of new cannabis cultivation facilities in
the U.S.
|
● |
In
the U.S., a total of 33 states (and the District of Columbia) have
legalized the medical use of cannabis for over 60 qualifying
conditions. Currently, 11 states (and the D.C.), have legalized
access to cannabis for recreational use. Now, 68% of the U.S.
population is living in a state that has legalized some form of
medical or recreational cannabis. |
|
|
|
|
● |
67%
of Americans support full legalization of cannabis, more than
double the 31% support in 2000. With increasing consumer acceptance
of cannabis and the growth of the industry as a whole, we believe
the number of states that allow cannabis use will likely jump even
higher in 2020. Consider the following data gathered from various
industry sources and publications: In the U.S., more than 24
million persons, or 9.9% of adults age 18 and over consume cannabis
regularly, and 115 million report consuming it in their lifetime.
There were 2.3 million registered U.S. medical cannabis patients in
2019, up 31% since 2014. |
|
|
|
|
● |
In
states where cannabis is currently legal, sales of medical and
recreational cannabis are forecasted to grow from $17 billion in
2020 to $30 billion in 2025. |
|
|
|
|
● |
Currently,
18 states are actively debating whether to legalize cannabis for
medical or adult-use. There is legislation or referenda being
considered in 11 states to legalize cannabis for recreational
purposes, including Arizona, New Jersey and New York. There is also
legislation or referendums being considered in 7 states to legalize
cannabis for medicinal purposes, including South Dakota, Virginia
and Georgia. If all 18 states in question were to legalize
programs, industry sources believe these states could collectively
add $11.4 billion in annual sales to the legal U.S. market by their
fourth year of operation. |
|
|
|
|
● |
As of
January 16, 2020, there were 975 cannabis-related bills moving
through state legislatures and Congress for 2020
sessions. |
The
following table sets forth our commercial-scale project bookings,
which we define as contracts executed with a value over $100,000
for which we received an initial deposit, by country/state for the
years 2016 through 2019. Based on the current economic climate and
our downsizing measures, there is no assurance that we will be able
to continue to obtain the level of bookings that we had in the
past.
|
|
Number of
New Commercial-Scale Project Bookings |
|
|
|
2019 |
|
|
2018 |
|
|
2017 |
|
|
2016 |
|
|
Total |
|
Canada |
|
|
9 |
|
|
|
10 |
|
|
|
7 |
|
|
|
1 |
|
|
|
27 |
|
California |
|
|
4 |
|
|
|
3 |
|
|
|
- |
|
|
|
3 |
|
|
|
10 |
|
Michigan |
|
|
6 |
|
|
|
4 |
|
|
|
- |
|
|
|
- |
|
|
|
10 |
|
Colorado |
|
|
1 |
|
|
|
- |
|
|
|
2 |
|
|
|
3 |
|
|
|
6 |
|
Washington |
|
|
- |
|
|
|
2 |
|
|
|
1 |
|
|
|
3 |
|
|
|
6 |
|
Oregon |
|
|
- |
|
|
|
- |
|
|
|
2 |
|
|
|
2 |
|
|
|
4 |
|
Alaska |
|
|
1 |
|
|
|
- |
|
|
|
1 |
|
|
|
2 |
|
|
|
4 |
|
Arizona |
|
|
- |
|
|
|
- |
|
|
|
2 |
|
|
|
1 |
|
|
|
3 |
|
Nevada |
|
|
1 |
|
|
|
- |
|
|
|
1 |
|
|
|
1 |
|
|
|
3 |
|
Ohio |
|
|
1 |
|
|
|
1 |
|
|
|
- |
|
|
|
- |
|
|
|
2 |
|
Rhode
Island |
|
|
- |
|
|
|
1 |
|
|
|
1 |
|
|
|
- |
|
|
|
2 |
|
New
Mexico |
|
|
1 |
|
|
|
1 |
|
|
|
- |
|
|
|
- |
|
|
|
2 |
|
Massachusetts |
|
|
- |
|
|
|
1 |
|
|
|
- |
|
|
|
- |
|
|
|
1 |
|
Texas |
|
|
- |
|
|
|
- |
|
|
|
1 |
|
|
|
- |
|
|
|
1 |
|
Hawaii |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
1 |
|
|
|
1 |
|
Wisconsin |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
1 |
|
|
|
1 |
|
Maryland |
|
|
- |
|
|
|
1 |
|
|
|
- |
|
|
|
- |
|
|
|
1 |
|
Arkansas |
|
|
- |
|
|
|
1 |
|
|
|
- |
|
|
|
- |
|
|
|
1 |
|
Oklahoma |
|
|
1 |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
1 |
|
Minnesota |
|
|
1 |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
1 |
|
Total |
|
|
26 |
|
|
|
25 |
|
|
|
18 |
|
|
|
18 |
|
|
|
87 |
|
Depending
on the state of our operations, our marketing efforts will
be targeted at MFOs, smaller independent growers, architects
working in the cannabis industry, investors and cannabis consulting
firms that are actively seeking licenses to produce cannabis in
California, Michigan, Missouri, Oklahoma, Massachusetts, Florida,
Utah and Illinois. We believe these represent the largest markets,
based on the state and local regulatory framework, for our products
and services. However, as and when new states pass legislation, we
will shift our priorities and/or add new salespeople to pursue new
facility construction at the early stage. We believe our marketing
efforts will be curtailed for the foreseeable future due to our
recent workforce reduction and our efforts to preserve our cash
resources as we deal with the uncertainty surrounding the
coronavirus.
In
the second half of 2019, we noticed softening demand from Canadian
prospects due, in part, to limited capital being available for new
facilities and an overbuilding of cultivation capacity following
federal legalization in October 2018. As a result, Canada now
appears to be in a period of correction. By contrast, cultivators
in the United States were unable to raise capital so readily, and
thus some states are under supplied with cannabis product. We
believe this supply imbalance could bode well for companies such as
ours as we expect that additional cultivation capacity will be
required to meet demand.
Retrofit Market
Existing
commercial retrofit projects also represent a business opportunity.
The estimated 3,000+ existing commercial grow facilities in North
America are easier to identify than new build projects. We believe,
based on evidence and our market knowledge, that some of these
exiting facilities are operating sub-optimally and have
environmental control problems that our products can help
remediate. We also believe that the energy consumption of these
facilities can be reduced, and we have commenced developing
services and products to help them realize savings. We have a full
product and service offering in mind, but we expect that the
roll-out will take up to two years. However, to expedite this
roll-out, we are evaluating possible strategic partners that could
add products and services that are an immediate value-add to our
customers.
We believe
the industry is beginning to recognize the need for our specialized
know-how and experience. Although we began targeting this retrofit
market segment in 2019, we have only completed one retrofit project
to date. We plan to continue our targeted outreach to the operators
of these first-generation facilities, although this outreach may be
limited based on the current economic climate and our recent
downsizing. These facility retrofit projects do not typically carry
the uncertainties associated with new build projects such as
licensing, permitting and funding. In the future, we also hope to
launch an internally developed facility assessment and analysis
tool to assist existing facilities in solving their environmental
controls challenges.
Our Sales Team
Following
our downsizing, our sales team consists of
two national accounts representatives, one regional salesperson and
our Chief Executive Officer.
Marketing Strategy
Our
marketing outreach is conducted primarily through five primary
channels: print advertisement, digital advertisement, our website,
social media and industry trade shows.
Print
Advertisement. We advertise in major industry trade
publications such as Cannabis Business Times, Cannabis Tech, Grow
Opportunity (Canada), and MJBiz Daily.
Digital
Advertisement. We use digital advertising across a larger array
of publications. Digital advertising may consist of Surna banners,
newsletters, e-blasts and leaderboards on MJBiz Daily, Grow
Opportunity, Cannabis Prospect, Cannabis Tech, Contact Canada,
Cannabis Business Times, Cultivate and MMJ
Daily.
Website. Our
website is a consistent source of leads. We revamped our website in
2019 consistent with our new marketing methodology to better
identify customer prospects earlier in the cultivator’s vendor
decision-making and engagement process.
Social
Media. While there are still challenges in this industry to
fully take advantage of social media advertising, it is still a
meaningful channel to communicate directly with our customers and
prospects, we continue to grow our follower base and regularly
communicate via Facebook, Twitter, LinkedIn and
Instagram.
Trade
Shows. We display at industry trade shows and conventions and
conduct speaking engagements to achieve industry visibility and
presence in a cost-effective manner.
New
Build Facility Sales Cycle and Risks
The
sales cycles for our new build commercial projects can vary
significantly. From pre-sales and technical advisory meetings to
sales contract execution, to engineering and design services and
equipment delivery, and all the way through installation and
commissioning of the installed system, the full cycle can range
from six months to two years. Since we do not install the climate
control systems, our customers are required to use third-party
installation contractors, which adds to the variability of the
sales cycle.
The
length of our sales cycle for new facilities is driven by numerous
factors including:
|
● |
the
large number of first-time participants interested in the indoor
cannabis cultivation business; |
|
● |
the
complexities and uncertainties involved in obtaining state and
local licensure and permitting; |
|
● |
local
and state government delays in approving licenses and permits due
to lack of staff or the large number of pending applications,
especially in states where there is no cap on the number of
cultivators; |
|
● |
the
customer’s need to obtain cultivation facility
financing; |
|
● |
the
time needed, and coordination required, for our customers to
acquire real estate and properly design and build the facility (to
the stage where climate control systems can be
installed); |
|
● |
the
large price tag and technical complexities of the climate control
and air sanitation system; |
|
● |
availability
of power; and |
|
● |
delays
that are typical in completing any commercial construction
project. |
As a
result of the foregoing, there are risks that we may not realize
the full contract value of our backlog in a timely manner, or at
all. The performance of our obligations under a sales contract, and
the timing of our revenue recognition, is dependent upon our
customers’ ability to secure funding and real estate, obtain a
license and then build their cultivation facility so they can take
possession of the equipment—each of which are outside of our
control. More recently, as some of our new construction facility
projects have become larger and more complex, the likelihood of
delays—due to licensing and permitting, lack of or delay in
funding, staged facility construction, and/or the shifting
priorities of certain customers with multiple facility projects in
progress at one time—has increased.
In
order to address these risks, the obligations under our sales
contracts are generally allocated into the following types of
deliverables, and we typically require non-refundable payments from
our customers in advance of our performance of services or delivery
of equipment. However, in certain situations, especially as we
expand our products and services offering for a customer’s entire
facility lifecycle, we may extend credit to our customers in which
case we are at risk for the collection of account
receivables.
Engineering Services. We provide our customer with
engineering and design services and drawings. In many cases, the
engineering phase is done as part of the license application or
building permit process and takes approximately six to eight weeks
to complete. Our strategy is to secure the sales contract and
commence the engineering and design portion of the project early in
the customer’s planning phase of the project. This is important for
a number of reasons: (i) we can assist our customers with their
engineering and design plans as part of their licensing application
process as well as better assure the customer has the right-sized
equipment for their application, leading to a higher probability of
a successful grow, (ii) we are better positioned to utilize our
proprietary equipment for the project at an earlier stage, and
(iii) we are able to help reduce a customer’s time to market.
Before we commence the engineering phase of the project, we will
generally require an advanced payment intended to cover the
engineering value of the contract.
Surna Manufactured Equipment. Upon completion of the
engineering and design phase, it may take our customer on average
six to 12 months to complete the facility build-out, with possible
delays due to financing or other aspects which are beyond our
control as discussed above. Customer delays in obtaining financing
and completing facility build-out make the completion timing of our
sales contract unpredictable. For this reason, we require an
additional advance payment before we begin manufacturing our
proprietary equipment items.
Third-Party Manufactured Equipment. The final phase of our
contract typically involves the delivery of third-party
manufactured equipment items and other equipment to complete the
project. We typically will not deliver until we receive a final
advance payment for the remaining contract value. After the project
is completed and the environmental control system has been fully
installed by third-party installation contractors, we will deploy
our technicians to the customer’s cultivation facility to
“commission” the system. Commissioning involves testing that the
equipment has been properly assembled and installed by the
installation contractor and assuring the equipment is operating
within the agreed specifications.
Given
the timing of the deliverables of our sales contracts, we have
often experienced large variances in quarterly revenue. Our revenue
recognition is dependent upon shipment of the equipment portions of
our sales contracts, which, in many cases, may be delayed while our
customers complete permitting, prepare their facilities for
equipment installation or obtain project financing.
Competition
Our
environmental control systems and our related engineering and
design services compete with various national and local HVAC
contractors and traditional HVAC equipment suppliers who
traditionally resell, design, and implement climate control systems
for commercial and industrial facilities, most of whom do not have
the specific knowledge that we have about the complexities and
challenges of cannabis cultivation. We have positioned ourselves to
differ from these competitors by providing engineering and design
services and environmental control systems, across all HVAC
solutions, including modular chilled water systems, custom air
handling units, split systems, packaged roof-top units, and
self-contained and complex chilled-water systems, each tailored
specifically for managing the distinct challenges involved in
indoor cannabis cultivation. We believe our cannabis-specific
applications and experience in this market allow us to deliver the
right solution to our cultivation customers. Unlike many of our
competitors, our solutions are designed specifically for
cultivators to provide tight temperature/humidity control, reduce
bio-security risk, reduce energy requirements, and minimize
maintenance complexity, costs and downtime. However, we are seeing
more direct competitors enter into the cannabis market offering the
same cannabis-specific climate control systems and engineering
services that we offer. We believe this increased competition may
adversely impact our ability to obtain new facility projects from
both MFOs and independent smaller growers and could require us to
accept lower gross margins on our projects.
Intellectual
Property
We
rely on a combination of patent and trademark rights, licenses,
trade secrets, laws that protect intellectual property,
confidentiality procedures, and contractual restrictions with our
employees and others to establish and protect our intellectual
property rights. We have several issued patents and pending patent
applications; however, we do not believe that these issued and
pending patents currently provide us with any competitive
advantage. We have registered trademark registrations around our
core Surna brand (“Surna”) in the United States and select foreign
jurisdictions, as well as the Surna logo and the combined Surna
logo and name in the United States. Our trademark is also
registered in the European Union and Canada. Subject to ongoing use
and renewal, trademark protection is potentially perpetual. We
actively protect our inventions, new technologies, and product
developments by maintaining trade secrets and, in limited
circumstances, filing for patent protection.
Employees
Following
our workforce reduction, we currently have 15
active full-time employees and eight part-time employees. However,
we may engage, and have in the past utilized, the services of
consultants, independent contractors, and other non-employee
professionals. Additional employees may be hired in the future
depending on need, available resources, and our achieved
growth.
Government
Regulation
The
use, possession, cultivation, and distribution of marijuana is
prohibited by U.S. federal law for medical and recreational
purposes. Although certain states have legalized medical and
recreational cannabis, companies and individuals involved in the
sector are still at risk of being prosecuted by federal
authorities. Further, the landscape in the cannabis industry
changes rapidly. This means that at any time the city, county, or
state where cannabis is permitted can change the current laws
and/or the federal government can supersede those laws and take
prosecutorial action. Given the uncertain legal nature of the
cannabis industry, it is imperative that investors understand that
investments in the cannabis industry should be considered very high
risk. A change in the current laws or enforcement policy can
negatively affect the status and operation of our business, require
additional fees, stricter operational guidelines and unanticipated
shut-downs.
See
the “Risks Related to the Cannabis Industry” set forth in
Item 1A of this Annual Report which addresses various risks related
to U.S. and foreign regulation and enforcement of cannabis laws and
regulations and their potential impact on our business.
Available
Information
Our
website address is www.surna.com. Our Annual Report on Form
10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K,
and amendments to reports filed pursuant to Sections 13(a) and
15(d) of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), are filed with the U.S. Securities and Exchange
Commission (the “SEC”). Such reports and other information filed by
us with the SEC are available free of charge through our website
when such reports are available on the SEC’s website.
The
SEC maintains an Internet site that contains reports, proxy and
information statements and other information regarding issuers that
file electronically with the SEC at www.sec.gov.
The
contents of the websites referred to above are not incorporated
into this filing. Further, references to the URLs for these
websites are intended to be inactive textual references
only.
Item 1A. Risk Factors
Investing
in our common stock involves significant risks. Certain factors may
have a material adverse effect on our business, financial
condition, and results of operations. You should consider carefully
the risks and uncertainties described below, in addition to other
information contained in this Annual Report on Form 10-K, including
our consolidated financial statements and related notes. The risks
and uncertainties described below are not the only ones we face.
Additional risks and uncertainties that we are unaware of, or that
we currently believe are not material, may also become important
factors that adversely affect our business. If any of the following
risks actually occurs, our business, financial condition, results
of operations, and future prospects could be materially and
adversely affected. In that event, the trading price of our common
stock could decline, and you could lose part or all of your
investment.
Risks
Relating to Our Business
Our revenues have been limited, and we will need to obtain
financing for future growth, and possibly our operations, which may
not be available to us and could dilute the ownership of current
shareholders.
Historically,
we have raised equity and debt capital to support our operations.
We anticipate we will require additional cash resources to finance
our growth or other future developments, including the launch of
any new products and services and any investments or acquisitions
we may decide to pursue. As of December 31, 2019, we had a working
capital deficit of approximately $1,437,000 and our cash balance
was $922,000. We are likely to need additional funds to complete
further development of our business plan to achieve a sustainable
sales level where ongoing operations can be funded from operations.
We currently have no debt obligations. We will likely need to raise
debt or equity financing in the future in order to continue our
operations and achieve our growth targets. However, there can be no
assurance that such financing will be available in sufficient
amounts and on acceptable terms, when and if needed, or at all. The
precise amount and timing of our funding needs cannot be determined
accurately at this time, and will depend on a number of factors,
including market demand for our products and services, the success
of our product development efforts, the timing of receipts for
customer payments, the management of working capital, and the
continuation of normal payment terms and conditions for our
purchase of goods and services. The continuation of normal payment
terms and conditions with our customers and suppliers, including
our ability to obtain advance payments from our customers,
significantly impacts our ability to fund our ongoing operations.
We believe our cash balances and cash flow from operations will be
insufficient to fund our operations and growth for the next 12
months.
To
the extent that we raise additional equity capital, existing
shareholders will experience a dilution in the voting power and
ownership of their common stock, and earnings per share, if any,
would be negatively impacted. Our inability to use our equity
securities to finance our operations could materially limit our
growth. Any borrowings made to finance operations, which are
difficult to obtain from most traditional banks due to the federal
laws prohibiting cannabis use, could make us more vulnerable to a
downturn in our operating results, a downturn in economic
conditions, or increases in interest rates on borrowings that are
subject to interest rate fluctuations. The amount and timing of
such additional financing needs will vary principally depending on
the timing of new product launches, investments and/or
acquisitions, and the amount of cash flow from our operations. If
our resources are insufficient to satisfy our cash requirements, we
may seek to issue additional equity or debt securities or obtain a
credit facility.
Due
to the heightened uncertainty relating to the potential impacts of
the coronavirus on our business operations and other headwinds
affecting the cannabis industry, we recently implemented a
workforce reduction which could adversely impact our day-to-day
operations, including our sales and project management activities,
and we may not be able to continue our
operations.
A number
of recent events have had an adverse impact on our operations and
financial condition, including constraints on capital availability
for our customers and prospects who have commenced, or are
contemplating, new and expanded cannabis cultivation facilities and
the recent outbreak of COVID-19, a novel strain of coronavirus
first identified in China, which has spread across the globe
including the U.S. Most recently, the response to this coronavirus
by federal, state and local governments in the U.S. has resulted in
significant market and business disruptions across many industries
and affecting businesses of all sizes. This pandemic has also
caused significant stock market volatility and further tightened
capital access for most businesses.
As a
result of these events, we assessed our near-term operations,
working capital, finances and capital formation opportunities, and
implemented, in late March 2020, a downsizing of our operations and
workforce to preserve cash resources and focus our operations on
customer-centric sales and project management activities. The
duration and likelihood of success of this workforce reduction are
uncertain. If this downsizing effort does not meet our
expectations, or additional capital is not available, we may not be
able to continue our operations. Other factors that will affect our
ability to continue operations include the market demand for our
products and services, our ability to service the needs of our
customers and prospects with a reduced workforce, potential
contract cancellations, project scope reductions and project
delays, our ability to fulfill our current backlog, management of
our working capital, the availability of cash to fund our
operations, and the continuation of normal payment terms and
conditions for purchase of our products. In light of these
extenuating circumstances, there is no assurance that we will be
successful in growing and maintaining our business with MFOs and
independent smaller growers. Due to the heightened uncertainty
relating to the potential impacts of the coronavirus on our
business operations, we believe our cash balances and cash flow
from operations will be insufficient to fund our operations for the
next twelve months. If our customers or prospects are unable to
obtain project financing and we are unable to increase revenues, or
otherwise generate cash flows from operations, we will not be able
to successfully execute on the various strategies and initiatives
we have set forth in this Annual Report to grow our business. The
extent to which the coronavirus will impact our business and our
financial results will depend on future developments, which are
uncertain and cannot be predicted at this time.
Our independent registered public accounting firm has expressed
substantial doubt about our ability to continue as a going
concern.
We
have determined that our ability to continue as a going concern is
dependent on raising additional capital to fund our operations and
ultimately on generating future profits. Our independent registered
public accounting firm has also included a “going concern”
explanatory paragraph in its opinion on our financial statements,
expressing substantial doubt that we can continue as an ongoing
business for the next 12 months. Our financial statements do not
include any adjustments that may result from the outcome of this
uncertainty. If we are unable to successfully raise the capital we
need, we may need to and believe we can reduce the scope of our
business to fully satisfy our future short-term liquidity
requirements. If we cannot raise additional capital or reduce the
scope of our business, we may be otherwise unable to achieve our
goals or continue our operations. While we believe that we will be
able to raise the capital we need to continue our operations, there
can be no assurances that we will be successful in these efforts or
will be able to resolve our liquidity issues or eliminate our
operating losses.
Even if we obtain more customers, there is no assurance that we
will be able to convert our backlog into revenue or make a
profit.
We
may be unable to convert the full contract value of our backlog in
a timely manner, or at all. The performance of our obligations
under a sales contract, and the timing of our revenue recognition,
is dependent upon our customers’ ability to secure funding and real
estate, obtain a license and then build their cultivation facility
so they can take possession of the equipment. Our sales contracts
currently are not time specific as to when our customers are
required to take delivery of our services and equipment. More
recently, we determined that some of our new construction facility
projects are becoming larger and more complex and, as a result,
delays were more likely due to licensing and permitting, lack of or
delay in funding, staged facility construction, and/or the shifting
priorities of certain customers with multiple facility projects in
progress at one time. Even if we obtain more customers, or increase
the average size of our projects, there is no guarantee that we
will be able to generate a profit. Because we are a small company
with limited capital, limited products and services, and limited
marketing activities, we may not be able to generate sufficient
revenue to operate profitably. If we cannot operate profitably, we
may have to suspend or cease operations.
We may extend credit to our customers in the future and, if we are
unable to collect these accounts receivable, our future
profitability could be adversely impacted.
Historically,
we had little exposure to the collection risk on accounts
receivable since we typically received payments from our customers
in advance of our performance of services or delivery of equipment.
However, in certain situations, especially as we expand our
products and services offering for a customer’s entire facility
lifecycle, we may extend credit to our customers in which case we
are at risk for the collection of account receivables. Accordingly,
we will be at greater risk for the collection of account
receivables. Our credit arrangements are negotiated and may not
protect us if a customer develops operational difficulty or incurs
operating losses which could lead to a bankruptcy. In these cases,
we may lose most of the outstanding balance due. In addition, we
are typically not able to insure our accounts receivables. The risk
is that we derive our revenue and profits from selling products and
services to the emerging cannabis industry. The failure of our
customers to pay in full amounts due to us could negatively affect
future profitability.
Because we currently do not maintain effective internal controls
over financial reporting, we may be unable to accurately report our
financial results or prevent fraud, and investor confidence and the
market price of our common stock may, therefore, be adversely
impacted.
Our
reporting obligations as a public company place a significant
strain on our management, operational and financial resources, and
systems, and will continue to do so for the foreseeable future.
Annually, we are required to prepare a management report on our
management’s assessment of the effectiveness of our internal
control over financial reporting. Management has concluded that our
internal control over financial reporting is currently not
effective and shall report such in management’s report in this
annual report on Form 10-K. In the event that our status with the
SEC changes to that of an accelerated filer from a smaller
reporting company, our independent registered public accounting
firm will be required to attest to and report on our management’s
assessment of the effectiveness of our internal control over
financial reporting. Under such circumstances, even if our
management concludes that our internal control over financial
reporting is effective, our independent registered public
accounting firm may still decline to attest to our management’s
assessment, or may issue a report that is qualified, if it is not
satisfied with our controls, or the level at which our controls are
documented, designed, operated or reviewed, or if it interprets the
relevant requirements differently from us.
We have identified a material weakness in our internal control over
financial reporting and, if we do not remediate the material
weakness or are unable to implement and maintain effective internal
control over financial reporting in the future, the accuracy and
timeliness of our financial reporting may be adversely
affected.
We
currently do not maintain effective controls over certain aspects
of the financial reporting process because: (i) we lack a
sufficient complement of personnel with a level of accounting
expertise and an adequate supervisory review structure that is
commensurate with our financial reporting requirements, (ii) there
is inadequate segregation of duties due to the limitation on the
number of our accounting personnel, and (iii) we have insufficient
controls and processes in place to adequately verify the accuracy
and completeness of spreadsheets that we use for a variety of
purposes including revenue, taxes, stock-based compensation and
other areas, and place significant reliance on, for our financial
reporting. A material weakness is a deficiency or a combination of
deficiencies in internal control over financial reporting such that
there is a reasonable possibility that a material misstatement of
the annual or interim consolidated financial statements will not be
prevented or detected on a timely basis. If we are unable to
achieve effective internal control over financial reporting, or if
our independent registered public accounting firm determines we
continue to have a material weakness in our internal control over
financial reporting, we could lose investor confidence in the
accuracy and completeness of our financial reports, the market
price of our shares could decline, and our reputation may be
damaged.
Our inability to effectively manage our growth could harm our
business and materially and adversely affect our operating results
and financial condition.
Our
strategy envisions growing our business. We plan to expand our
product, sales, administrative and marketing operations. Any growth
in or expansion of our business is likely to continue to place a
strain on our management and administrative resources,
infrastructure and systems. As with other growing businesses, we
expect that we will need to further refine and expand our business
development capabilities, our systems and processes and our access
to financing sources. We also will need to hire, train, supervise,
and manage new employees. These processes are time consuming and
expensive, will increase management responsibilities and will
divert management attention. We cannot assure that we will be able
to:
|
● |
execute
on our business plan and strategy; |
|
|
|
|
● |
expand
our products effectively or efficiently or in a timely
manner; |
|
|
|
|
● |
allocate
our human resources optimally; |
|
|
|
|
● |
meet
our capital needs; |
|
|
|
|
● |
identify
and hire qualified employees or retain valued employees;
or |
|
|
|
|
● |
effectively
incorporate the components of any business or product line that we
may acquire in our effort to achieve growth. |
Our
inability or failure to manage our growth and expansion effectively
could harm our business and materially and adversely affect our
operating results and financial condition.
Our operating results may fluctuate significantly based on customer
acceptance of our products, industry uncertainty, project financing
concerns, and the licensing and qualification of our prospective
customers. As a result, period-to-period comparisons of our results
of operations are unlikely to provide a good indication of our
future performance.
Management
expects that, under typical operating conditions, we will
experience substantial variations in our revenues and operating
results from quarter to quarter. Our revenue recognition is
dependent upon shipment of the equipment portions of our sales
contracts, which, in many cases, may be delayed while our customers
complete permitting, prepare their facilities for equipment
installation or obtain project financing. Industry uncertainty,
project financing concerns, and the licensing and qualification of
our prospective customers, which are out of our control, make it
difficult for us to predict when we will recognize revenue. If
customers are unable to obtain licensing, permitting or financing,
our sales and revenue will decline, resulting in a reduction in our
operating income or possible increase in losses. Also, because of
the coronavirus responses and our own cost savings actions, we
cannot predict the course of our revenues and operating results
with accuracy at this time.
If we
do not successfully develop additional products and services, or if
such products and services are developed but not successfully
commercialized, we could lose revenue
opportunities.
Our
future success depends, in part, on our ability to expand our
product and service offerings. We are currently investigating a
number of new and improved product opportunities, and we intend to
collaborate with manufacturing partners to optimize these products
for the cannabis market. The processes of identifying and
commercializing new products is complex and uncertain, and if we
fail to accurately predict customers’ changing needs and emerging
technological trends our business could be harmed. We have already
and may have to continue to commit significant resources to
commercializing new products before knowing whether our investments
will result in products the market will accept. We may be unable to
differentiate our new products from those of our competitors, and
our new products may not be accepted by the market. There can be no
assurance that we will successfully identify additional new product
opportunities, develop and bring new products to market in a timely
manner, or achieve market acceptance of our products or that
products and technologies developed by others will not render our
products or technologies obsolete or noncompetitive. Furthermore,
we may not execute successfully on commercializing those products
because of errors in product planning or timing, technical hurdles
that we fail to overcome in a timely fashion, or a lack of
appropriate resources. This could result in competitors providing
those solutions before we do and a reduction in revenue and
earnings.
Our future success depends on our ability to grow and expand our
customer base. Our failure to achieve such growth or expansion
could materially harm our business.
Our
success and the planned growth and expansion of our business depend
on us achieving greater and broader acceptance of our products and
services and expanding our commercial customer base. There can be
no assurance our sales efforts will be successful. There can be no
assurance that customers will purchase our services or products or
that we will continue to expand our customer base. If we are unable
to effectively market or expand our product and service offerings,
we will be unable to grow and expand our business or implement our
business strategy. This could materially impair our ability to
increase sales and revenue, and materially and adversely affect our
margins, which could harm our business and cause our stock price to
decline.
Our suppliers could fail to fulfill our orders for parts used to
assemble our products, which would disrupt our business, increase
our costs, harm our reputation, and potentially cause us to lose
our market.
We
depend on third party suppliers around the world, including in The
People’s Republic of China, for materials used to assemble our
products. These suppliers could fail to produce products to our
specifications or in a workmanlike manner and may not deliver the
material or products on a timely basis. Our suppliers may also have
to obtain inventories of the necessary parts and tools for
production. Any change in our suppliers’ approach to resolving
production issues could disrupt our ability to fulfill orders and
could also disrupt our business due to delays in finding new
suppliers, providing specifications and testing initial
production.
Natural disasters, major health events, terrorist attacks or other
catastrophic events could harm our operations and our financial
results.
Our
operations could be subject to natural disasters, major health
events and other business disruptions, which could harm our future
revenue and financial condition and increase our costs and
expenses. For example, the recent outbreak of COVID-19, a novel
strain of coronavirus first identified in Wuhan, Hubei Province,
China, which has spread across the globe including the U.S., has
resulted in significant governmental measures being implemented to
control the spread of the virus, including restrictions on
manufacturing and the movement of employees in many regions of
China, Europe and elsewhere, including areas of the U.S. This could
affect the manufacturing facilities of our suppliers in China and
elsewhere and we believe will also unfavorably impact our
customers’ operations or prospects for project financing and
project completion. We also may experience contract cancellations
or project scope reductions. The coronavirus outbreak could also
disrupt and delay the production and shipment of our products,
which could result in delays in fulfilling orders and could harm
our reputation and potentially cause us to lose business. The
extent to which the coronavirus will impact our business and our
financial results will depend on future developments, which are
uncertain and cannot be predicted.
In
addition to the above, we have taken steps to reduce our staff and
implement other cost savings in our operations. These actions could
adversely impact our ability to timely fulfill our contract
obligations, continue our development activities and generally
carry on our operations.
International trade disputes could result in tariffs and other
protectionist measures that could adversely affect the Company’s
business.
Tariffs
could increase the cost of our products and the components and raw
materials that go into making them. These increased costs could
adversely impact the gross margin that we earn on sales of our
products. Tariffs could also make our products more expensive for
customers, which could make our products less competitive and
reduce customer demand. Countries may also adopt other
protectionist measures that could limit our ability to offer our
products and services.
Our inability to effectively protect our intellectual property
would adversely affect our ability to compete effectively, our
revenue, our financial condition, and our results of
operations.
We
may be unable to obtain intellectual property rights to effectively
protect our branding, products, and other intangible assets. Our
ability to compete effectively may be affected by the nature and
breadth of our intellectual property rights. While we intend to
defend against any threats to our intellectual property rights,
there can be no assurance that any such actions will adequately
protect our interests. If we are unable to secure intellectual
property rights to effectively protect our branding, products, and
other intangible assets, our revenue and earnings, financial
condition, or results of operations could be adversely
affected.
We
also rely on non-disclosure and non-competition agreements to
protect portions of our intellectual property portfolio. There can
be no assurance that these agreements will not be breached, that we
will have adequate remedies for any breach, that third parties will
not otherwise gain access to our trade secrets or proprietary
knowledge, or that third parties will not independently develop
competitive products with similar intellectual property.
Our industry is highly competitive, and we have less capital and
resources than many of our competitors, which may give them an
advantage in developing and marketing products similar to ours, or
make our products obsolete.
We
are involved in a highly competitive industry where we compete with
national and local HVAC contractors and traditional HVAC equipment
suppliers who offer products and services similar to those that we
sell. These competitors may have far greater resources than we do,
giving our competitors an advantage in developing and marketing
products and services similar to ours or products that make our
products obsolete. While we believe we are better positioned to
meet the exacting demands of a cannabis cultivation environment
through precise temperature, humidity, light, and process controls
and to satisfy the evolving code and regulatory requirements being
imposed at the state and local levels, there can be no assurance
that we will be able to successfully compete against these other
contractors and suppliers.
We will be required to attract and retain top quality talent to
compete in the marketplace.
We
believe our future growth and success will depend in part on our
ability to attract and retain highly skilled managerial, product
development, sales and marketing, and finance personnel. Our
ability to attract and retain personnel with the requisite
credentials, experience and skills will depend on several factors
including, but not limited to, our ability to offer competitive
wages, benefits and professional growth opportunities. There can be
no assurance of success in attracting and retaining such personnel.
Shortages in qualified personnel could limit our ability to
increase sales of existing products and services and launch new
product and service offerings.
We are dependent upon certain key sales, managerial and executive
personnel for our future success. If we lose any of our key
personnel, our ability to implement our business strategy could be
significantly harmed.
We depend
on the industry knowledge, technical and financial skill, and
network of business contacts of certain key employees. Our future
success will depend on the continued service of these key employees
or our ability to engage others who are similarly situated in the
industry. While we may have employment agreements with certain of
these key employees, they are free to terminate their employment
with us at any time, although they may be subject to certain
restrictive covenants on their post-termination activities. We do
not carry key-man life insurance on the lives of our key employees.
The departure of any one of our key employees could have a material
adverse effect on our ability to achieve our business objective and
maintain the specialized services that we offer our
customers.
System security risks, data protection breaches, cyber-attacks and
systems integration issues could disrupt our internal operations or
services provided to customers, and any such disruption could
reduce our expected revenue, increase our expenses, damage our
reputation and adversely affect our stock price.
Experienced
computer programmers and hackers may be able to penetrate our
network security and misappropriate or compromise our confidential
information or that of third parties, create system disruptions or
cause shutdowns. Computer programmers and hackers also may be able
to develop and deploy viruses, worms, and other malicious software
programs that attack or otherwise exploit any security
vulnerabilities of the products that we may sell in the future,
especially our recently launched SentryIQTM sensors,
controls and automation platform. The costs to us to eliminate or
alleviate cyber or other security problems, bugs, viruses, worms,
malicious software programs and security vulnerabilities could be
significant, and our efforts to address these problems may not be
successful and could result in interruptions, delays, cessation of
service and loss of existing or potential customers that may impede
our engineering, sales, manufacturing, distribution or other
critical functions.
Portions
of our IT infrastructure may also experience interruptions, delays
or cessations of service or produce errors in connection with
systems integration or migration work that takes place from time to
time. We may not be successful in implementing new systems and
transitioning data, which could cause business disruptions and be
more expensive, time consuming, disruptive and resource-intensive.
Such disruptions could adversely impact our ability to fulfill
orders and interrupt other processes. Delayed sales, lower profits,
or lost customers resulting from these disruptions could adversely
affect our financial results, stock price and
reputation.
We incur significant costs as a result of being a public company,
which will make it more difficult for us to achieve
profitability.
As a
public company, we incur legal, accounting and other expenses,
including costs associated with the periodic reporting requirements
applicable to a company whose securities are registered under the
Exchange Act, as well as additional corporate governance
requirements, including requirements under the Sarbanes-Oxley Act,
and other rules implemented by the SEC. These costs will make it
more difficult for us to achieve profitability.
Our ability to use net operating losses to offset future taxable
income may be subject to limitations.
As of
December 31, 2019, we had federal and state net operating loss
carryforwards of $16,355,000. Our ability to deduct these net
operating loss carryforwards against future taxable income is
contingent on our generation of future taxable income. Our federal
and state net operating loss carryforwards generated through
December 31, 2017 will expire, if not utilized, in the years 2034
through 2037. NOLs generated subsequent to December 31, 2017 do not
expire but may only be used against taxable income to 80%. These
net operating loss carryforwards could expire unused and be
unavailable to offset future income tax liabilities. Under the
recently enacted federal income tax law, federal net operating
losses incurred in 2018 and in future years may be carried forward
indefinitely, but the deductibility of such federal net operating
losses is limited. It is uncertain if and to what extent various
states will conform to the newly enacted federal tax law. In
addition, under Section 382 of the Internal Revenue Code of 1986,
as amended (the “Code”), and corresponding provisions of state law,
if a corporation undergoes an “ownership change,” which is
generally defined as a greater than 50% change, by value, in its
equity ownership over a three-year period, the corporation’s
ability to use its pre-change net operating loss carryforwards and
other pre-change tax attributes to offset its post-change income or
taxes may be limited. We have experienced ownership changes in the
past and we may experience additional ownership changes in the
future as a result of subsequent shifts in our stock ownership,
some of which may be outside of our control. If an ownership change
occurs and our ability to use our net operating loss carryforwards
is materially limited, it would harm our future operating results
by effectively increasing our future tax obligations.
Risks
Related to the Cannabis Industry
U.S. federal laws, regulations and enforcement may adversely affect
the implementation of state and local cannabis laws and regulations
and, correspondingly, may adversely impact our customers. Such
impact may negatively affect our revenue and profits, or we may be
found to be in violation of the Controlled Substances Act or other
U.S. federal, state or local laws.
Currently,
33 states and the District of Columbia permit some form of
whole-plant cannabis use and cultivation either for medical or
recreational use. There are efforts in many other states to begin
permitting cannabis use and/or cultivation in various contexts, and
there are a number of states actively considering bills to permit
recreational use. Nevertheless, the U.S. federal government
continues to prohibit cannabis in all its forms as well as its
derivatives. Under the federal Controlled Substances Act (the
“CSA”), the policy and regulations of the U.S. federal government
and its agencies is that marihuana, or its more commonly spelled
name marijuana, has no currently accepted medical use and a high
potential for abuse, and a range of activities, including
cultivation and use of marijuana, is prohibited.
In
December of 2018, the Agricultural Improvement Act of 2018 (the
“2018 Farm Act”) was enacted into law which included an amendment
to wholly remove “hemp” from the CSA and defined “hemp” as all
parts of a cannabis plant containing less than 0.3% of
tetrahydrocannabinol (“THC”) thereby excluding hemp and its
derivatives, including hemp-derived cannabidiol (“CBD”) oil, as a
“controlled substance.” Under the 2018 Farm Act, the cultivation of
hemp is no longer prohibited under federal law. Further, although
hemp-derived CBD is now federally legal under the 2018 Farm Act,
the U.S. Food and Drug Administration has regulatory oversight on
the use of hemp-derived CBD in food, beverage and dietary products
as well as any medical or therapeutic claims related thereto.
Cannabis-derived CBD oil remains federally illegal in the U.S.
However, state laws vary on the permitted sale and use of both
hemp-and cannabis-derived CBD oil.
Until
Congress amends the CSA or the executive branch de-schedules or
reschedules marijuana under it, there is a risk that federal
authorities may enforce current federal law. Enforcement of the CSA
by federal authorities could impair our revenue and earnings, and
it could even force us to cease operating entirely in the cannabis
industry. The risk of strict federal enforcement of the CSA in
light of congressional activity, judicial holdings and stated
federal policy, including enforcement priorities, remains
uncertain.
In an
effort to provide guidance to federal law enforcement, the U.S.
Department of Justice (the “DOJ”) issued Guidance Regarding
Marijuana Enforcement to all United States Attorneys in a
memorandum from Deputy Attorney General David Ogden on October 19,
2009, in a memorandum from Deputy Attorney General James Cole on
June 29, 2011 and in a memorandum from Deputy Attorney General
James Cole on August 29, 2013 (the “Cole Memo”). The Cole Memo also
provided guidance to federal prosecutors concerning cannabis
enforcement in light of state laws legalizing medical and
recreational cannabis possession in small amounts. Each memorandum
provided that the DOJ was committed to enforcement of the CSA, but
the DOJ was also committed to using its limited investigative and
prosecutorial resources to address the most significant threats in
the most effective, consistent and rational way.
The
Cole Memo sets forth certain enforcement priorities that are
important to the federal government:
|
● |
Distribution
of marijuana to children; |
|
|
|
|
● |
Revenue
from the sale of marijuana going to criminals; |
|
|
|
|
● |
Diversion
of medical marijuana from states where it is legal under state law
to states where it is not; |
|
|
|
|
● |
Using
state-authorized marijuana activity as a pretext for other illegal
drug activity; |
|
|
|
|
● |
Violence
in the cultivation and distribution of marijuana; |
|
|
|
|
● |
Drugged
driving and other adverse public health consequences; |
|
|
|
|
● |
Growing
marijuana on public lands; and |
|
|
|
|
● |
Possession
or use of marijuana on federal property. |
On
January 4, 2018, the Cole Memo was rescinded by Attorney General
Jeff Sessions (the “Sessions Memo”). The effect of rescinding the
Cole Memo guidance is that U.S. Attorneys now have greater
discretion to prosecute CSA violations with respect to individuals
and companies that are otherwise complying with state law and the
tenets previously set forth in the Cole Memo. The DOJ has not
historically devoted resources to prosecuting individuals whose
conduct is limited to possession of small amounts of cannabis for
use on private property but relied on state and local law
enforcement to address that form of cannabis activity. In the event
the DOJ goes beyond the objectives of the Cole Memo guidance and
begins strict enforcement of the CSA in states that have laws
legalizing medical and recreational cannabis in small amounts,
there may be a direct and adverse impact to our revenue and
earnings, and it could even force us to cease operating entirely in
the cannabis industry.
In
2014, the U.S. House of Representatives passed an amendment (the
“Rohrabacher-Farr Amendment”) to the Commerce, Justice, Science,
and Related Agencies Appropriations Bill, which funds the DOJ. The
Rohrabacher-Farr Amendment prohibits the DOJ from using federally
appropriated funds to prevent states with medical cannabis laws
from implementing such laws by investigating and prosecuting
individuals or businesses operating in accordance with applicable
state laws. In August 2016, a Ninth Circuit federal appeals court
ruled in United States v. McIntosh that the Rohrabacher-Farr
Amendment bars the DOJ from spending funds on the prosecution of
conduct that is allowed by state medical cannabis laws, provided
that such conduct is in strict compliance with applicable state
law. In March 2015, bipartisan legislation titled the Compassionate
Access, Research Expansion, and Respect States Act (the “CARERS
Act”) was introduced, proposing to allow states to regulate the
medical use of cannabis by changing applicable federal law,
including reclassifying cannabis under the CSA to a Schedule II
controlled substance and thereby changing the plant from a
federally-criminalized substance to one that has recognized medical
uses.
Although
these developments have been met with a certain amount of optimism
in the scientific community, the CARERS Act has not yet been
adopted, and the Rohrabacher-Farr Amendment, as an amendment to an
appropriations bill, must be renewed annually on a bipartisan basis
in order to remain in effect. The Rohrabacher-Farr Amendment has
been renamed the Rohrabacher-Blumenauer Amendment through the
amendment language, but the intent remains the same. The currently
enacted Commerce, Justice, Science, and Related Agencies Act, which
includes the Rohrabacher-Blumenauer Amendment, is effective, by
passage of continuing resolutions, through September 30, 2020.
Following the Sessions Memo, however, the federal government could
at any time change its enforcement priorities against the cannabis
industry. Any change in enforcement priorities could render our
operations unprofitable or even prohibit such
operations.
The
former Obama administration effectively stated that it is not an
efficient use of resources to direct federal law enforcement
agencies to prosecute those lawfully abiding by state-designated
laws allowing the use and distribution of medical marijuana.
However, as discussed above, the Sessions Memo rescinded the Cole
Memo enforcement guidance. Any further change in enforcement policy
and a decision to enforce the federal laws more aggressively could
cause significant financial damage to us and our shareholders and
could adversely affect our ability to obtain equity or debt
financing, or even prohibit our operating in the cannabis industry
entirely.
In
June 2018, the Strengthening the Tenth Amendment Through Entrusting
States (the “STATES Act”) was introduced that would recognize
legalization of cannabis and the U.S. state laws that have
legalized it through their legislatures or citizen initiatives. The
STATES Act, if enacted into law, would amend the CSA to exempt from
federal enforcement individuals or corporations in states who are
in compliance with U.S. state, U.S. territory and the District of
Columbia, or tribal law on cannabis, with certain additional
provisions such as minimum ages.
We
have not requested or obtained any opinion of counsel or ruling
from any authority to determine if our operations are in compliance
with or violate any state or federal laws or whether we are
assisting others to violate a state or federal law. In the event
that our operations are deemed to violate any laws or if we are
deemed to be assisting others to violate a state or federal law, we
could have liability that could cause us to modify or cease our
operations.
Our business efforts in Canada present opportunities, but no
assurance can be given that our revenues and earnings will be
improved on the basis of our addressing the Canadian
business.
In
addition to U.S. operations, we seek to sell products and services
to cannabis growers in Canada, where medical and recreational
cannabis has been legal since 2018 across the country both
federally and provincially (subject to certain restrictions
relating to CBD). We believe Canada, with its federal legal regime,
represents a business opportunity for us, but we have noticed
softening demand from Canadian prospects due, in part, to limited
capital being available for new facilities and an overbuilding of
cultivation capacity following federal legalization. As a result,
Canada now appears to be in a period of correction. There can be no
assurance that we will be able to make any additional sales of
products or services in Canada.
Successful litigation by non-cannabis states affected by cannabis
legalization could have significant adverse effects on our
business.
Due
to variations in state law among states sharing borders, certain
states which have not approved any legal sale of cannabis may seek
to overturn laws legalizing cannabis use in neighboring states. For
example, in December 2014, the attorney general of each of Nebraska
and Oklahoma filed a complaint with the U.S. Supreme Court against
the state of Colorado arguing that the Supremacy Clause (Article VI
of the U.S. Constitution) prohibits Colorado from passing laws that
conflict with federal anti-drug laws and that Colorado’s laws are
increasing cannabis trafficking in neighboring states that maintain
cannabis bans, thereby putting pressure on such neighboring states’
criminal justice systems. In March 2016, the U.S. Supreme Court,
voting 6-2, declined to hear this case, but there is no assurance
that it will do so in the future. Additionally, nothing prevents
states’ attorneys general from using the same or similar cause of
action for a lawsuit in a lower federal or other court.
Previously,
the U.S. Supreme Court has held that drug prohibition is a valid
exercise of federal authority under the commerce clause; however,
it has also held that an individual state itself is not required to
adopt or enforce federal laws with which it disagrees. If the U.S.
Supreme Court rules that a legal cannabis state’s legislation is
unconstitutional, that could result in legal action against other
states with laws legalizing medical and/or recreational cannabis
use. Successful prosecution of such legal actions by non-cannabis
states could have significant adverse effects on our
business.
Variations in state and local regulation and enforcement in states
that have legalized cannabis may impose certain restrictions on
cannabis-related activities that may adversely impact our revenue
and earnings.
Individual
state laws do not always conform to the federal standard or to
other states’ laws. A number of states have decriminalized cannabis
to varying degrees; other states have created exemptions
specifically for medical cannabis, and several have both
decriminalization and medical laws. Eleven states and the District
of Columbia have legalized the recreational use of cannabis and
various state legislatures are considering recreational use while
ballot measures regarding recreational use are likely to be
submitted to voters in 2020. Variations exist among states that
have legalized, decriminalized, or created medical cannabis
exemptions. For example, Alaska and Colorado have limits on the
number of cannabis plants that can be grown by an individual in the
home. In most states, the cultivation of cannabis for personal use
continues to be prohibited except by those states that allow
small-scale cultivation by the individual in possession of cannabis
for medicinal purposes or that person’s caregiver. Active
enforcement of state laws that prohibit personal cultivation of
cannabis may indirectly and adversely affect our revenue and
earnings.
As the possession and use of marijuana is illegal under the CSA, it
is possible that our manufacture and sale of equipment that is used
to cultivate marijuana may be deemed to be aiding and abetting
illegal activities. It is also possible that our products could be
considered “drug paraphernalia.”
Federal
practices could change with respect to providers of equipment
potentially usable by cultivators in the medical and recreational
cannabis industry, which could adversely impact us. Cannabis
growers use equipment that we offer for sale. While we are not
aware of any threatened or current federal or state law enforcement
actions against any supplier of equipment that might be used for
cannabis growing, law enforcement authorities, in their attempt to
regulate the illegal use of cannabis, may seek to bring an action
or actions against us, including but not limited to a claim of
aiding and abetting, or being an accessory to, another’s criminal
activities or that our products are considered “drug
paraphernalia.”
The
federal aiding and abetting statute, U.S. Code Title 18 Section
2(a), provides that anyone who “commits an offense against the
United States or aids, abets, counsels, commands, induces or
procures its commission, is punishable as a principal.” Under U.S.
Code Title 21 Section 863, the term “drug paraphernalia” means “any
equipment, product or material of any kind which is primarily
intended or designed for use in manufacturing, compounding,
converting, concealing, producing, processing, preparing,
injecting, ingesting, inhaling, or otherwise introducing into the
human body a controlled substance.” Any drug paraphernalia involved
in any violation of Section 863 shall be subject to seizure and
forfeiture upon the conviction of a person for such violation.
While Section 863(f) contains an exemption for any person
authorized by local, state or federal law to manufacture, possess,
or distribute such items, any such action may force us to cease
operations and our investors could lose their entire
investment.
A
risk exists that our activities could be deemed to be facilitating
the selling or distribution of cannabis in violation of the CSA, or
to constitute aiding or abetting, or being an accessory to, a
violation of the CSA. There is also a risk that our products could
be considered drug paraphernalia and could be subject to seizure.
We believe, however, that such risks are relatively low. Federal
authorities have not focused their resources on such tangential or
secondary violations of the CSA, nor have they threatened to do so,
with respect to the sale of equipment that might be used by
cannabis cultivators, or with respect to any supplies marketed to
participants in the medical and recreational cannabis industry. We
are unaware of such a broad application of the CSA or the seizure
of drug paraphernalia by federal authorities, and we believe that
such an attempted application would be uncustomary.
If
the federal government were to change its practices, or were to
expend its resources investigating and prosecuting providers of
equipment that could be usable by participants in the medical or
recreational cannabis industry, such action could have a materially
adverse effect on our operations, our customers, or the sales of
our products. As a result of such an action, we may be forced to
cease operations and our investors could lose their entire
investment.
The fact that we provide products and services to companies in the
cannabis industry may impact our ability to raise adequate capital
for future expansion, which could hinder our growth potential as
well as our revenue and earnings.
A
very large percentage, if not all, of our customers are operating
in an industry that is still illegal under U.S. federal law. With
the lingering uncertainty of federal enforcement, many potential
investors, especially institutional investors, either refuse to
invest in the industry or are very reluctant to make such
investments. Our inability to raise adequate capital for future
expansion could substantially hinder our growth potential as well
as our revenue and earnings.
Our success may be dependent on additional states legalizing
recreational and/or medical cannabis use.
Continued
development of the recreational and medical cannabis markets is
dependent upon continued legislative authorization of cannabis at
the state level for recreational and/or medical purposes. Any
number of factors could slow or halt the progress. Furthermore,
progress, while encouraging, is not assured, and the process
normally encounters set-backs before achieving success. While there
may be ample public support for legislative proposals, key support
must be created in the relevant legislative committee or a bill may
never advance to a vote. Numerous factors impact the legislative
process. Any one of these factors could slow or halt the progress
and adoption of cannabis for recreational and/or medical purposes,
which would limit the overall available market for our products and
services, which could adversely impact our business, revenue and
earnings.
Our customers may have difficulty accessing the service of banks,
which may make it difficult for them to purchase our products and
services.
As a
result of the federal illegality of marijuana, many banks do not
provide banking services to the cultivation and distribution
segments of the cannabis industry, the argument being that they
would be accepting for deposit funds derived from the operation of
a federally illegal business. On February 14, 2014, the U.S.
Department of the Treasury Financial Crimes Enforcement Network
(“FinCEN”) released guidance to banks “clarifying Bank Secrecy Act
(“BSA”) expectations for financial institutions seeking to provide
services to marijuana-related businesses.” In addition, there have
been legislative attempts to allow banks to transact business with
state-authorized cannabis businesses. While these are positive
developments, there can be no assurance that legislation will be
successful, or that, even with the FinCEN guidance, banks will
decide to do business with cannabis companies, or that, in the
absence of actual legislation, state and federal banking regulators
will not strictly enforce current prohibitions on banks handling
funds generated from an activity that is illegal under federal law.
Moreover, the FinCEN guidance may be rescinded or amended at any
time in order to reconcile the now conflicting guidance of the
Sessions Memo. At present, few banks have taken advantage of the
FinCEN guidance, resulting in many cannabis businesses still
operating on an all-cash basis. This makes it difficult for
cannabis businesses to manage their businesses, pay their employees
and taxes, and having so much cash on hand also creates significant
public safety issues. Many ancillary businesses that service
cannabis businesses have to deal with the unpredictability of their
clients or customers not having a bank account. The inability of
our customers to open bank accounts and otherwise access the
services of banks, including obtaining credit, may make it more
difficult and costly for them to operate and more difficult for
such customers to purchase our products and services, which could
materially harm our business, revenue and earnings.
We are subject to certain federal regulations relating to cash
reporting.
The
BSA, enforced by FinCEN, requires us to report currency
transactions in excess of $10,000, including identification of the
customer by name and social security number, to the Internal
Revenue Service. This regulation also requires us to report certain
suspicious activity, including any transaction that exceeds $5,000
that we know, suspect or have reason to believe involves funds from
illegal activity or is designed to evade federal regulations or
reporting requirements and to verify sources of funds. Substantial
penalties can be imposed against us if we fail to comply with this
regulation. If we fail to comply with these laws and regulations,
the imposition of a substantial penalty could have a material
adverse effect on our business, financial condition and results of
operations.
State and municipal governments in which our customers do business
or seek to do business may have or may adopt laws that adversely
affect our ability to do business with such
customers.
While
the federal government has the right to regulate and criminalize
cannabis, state and municipal governments may adopt or amend
additional laws and regulations that further criminalize or
adversely affect cannabis businesses. States that currently have
laws that decriminalize or legalize certain aspects of cannabis,
such as medical marijuana, could in the future, reverse course and
adopt new laws that further criminalize or adversely affect
cannabis businesses. Additionally, municipal governments in certain
states may have laws that adversely affect cannabis businesses,
even though there are no such laws at the state level. For example,
municipal governments may have zoning laws that restrict where
cannabis operations can be located and the manner and size of which
they can expand and operate. These municipal laws, like the federal
laws, may adversely affect our customers’ ability to do business.
Also, given the complexity and rapid change of the federal, state
and local laws pertaining to cannabis, our customers may incur
substantial legal costs associated with complying with these laws
and in acquiring the necessary state and local licenses required by
their business endeavors. All of the foregoing may impact our
customers’ ability to purchase our products and services, which may
adversely affect our business, revenue and earnings.
Most, if not all, of our customers are impacted by Section 280E of
the Code, which limits certain expenses marijuana companies can
deduct. This negative impact could affect the financial condition
of our customers, which in turn may negatively affect the ability
of our customers to purchase our products and
services.
Section
280E of the Code forbids businesses from deducting otherwise
ordinary business expenses from gross income associated with the
“trafficking” of Schedule I or II substances, as defined by the
CSA. The Internal Revenue Service (the “IRS”) has subsequently
applied Section 280E to state-legal cannabis businesses since
marijuana is still a Schedule I substance. Section 280E states that
no deductions should be allowed on any amount “in carrying on any
trade or business if such trade or business consists of trafficking
in controlled substances.” Section 280E affects all businesses that
engage in the cultivation, sale or processing of marijuana. This
includes cultivators, medical dispensaries, marijuana retail stores
and infused product manufacturers, as well as marijuana-derived
concentrates and oil manufacturers. Because Section 280E limits
certain deductions, it can have a dramatic effect on the
profitability of these businesses, which in turn may adversely
affect their ability to purchase our products and services. Such
result may adversely impact our revenue and earnings.
Due to our involvement in the cannabis industry, we may have a
difficult time obtaining the various insurances that are desired to
operate our business, which may expose us to additional risk and
financial liability
Insurance
that is otherwise readily available, such as general liability and
directors’ and officers’ insurance, is more difficult for us to
find, and more expensive, because we are product and service
providers to companies in the cannabis industry. There are no
guarantees that we will be able to find such insurances in the
future, or that the cost will be affordable to us. If we are forced
to go without such insurances, it may prevent us from entering into
certain business sectors, may inhibit our growth, and may expose us
to additional risk and financial liabilities.
Risks
Related to Our Common Stock
Our common stock price may be volatile and may decrease
substantially.
The
trading price of our common stock has fluctuated substantially, and
we expect that it will continue to do so. The price of our common
stock in the market on any particular day depends on many factors
including, but not limited to, the following:
|
● |
price
and volume fluctuations in the overall stock market from time to
time; |
|
|
|
|
● |
investor
demand for our shares; |
|
|
|
|
● |
significant
volatility in the market price and trading volume of companies in
the cannabis industry; |
|
|
|
|
● |
variations
in our operating results and market conditions specific to our
business; |
|
|
|
|
● |
the
emergence of new competitors or new technologies; |
|
|
|
|
● |
operating
and market price performance of other companies that investors deem
comparable; |
|
|
|
|
● |
changes
in our Board of Directors or management; |
|
|
|
|
● |
sales
or purchases of our common stock by insiders, including sales of
our common stock issued to employees, directors and consultants
under our equity incentive plan which were registered under the
Securities Act of 1933, as amended (the “Securities Act”) under our
S-8 registration statement; |
|
|
|
|
● |
commencement
of, or involvement in, litigation; |
|
|
|
|
● |
changes
in governmental regulations, in particular with respect to the
cannabis industry; |
|
|
|
|
● |
actual
or anticipated changes in our earnings, and fluctuations in our
quarterly operating results; |
|
|
|
|
● |
market
sentiments about the cannabis industry; |
|
|
|
|
● |
general
economic conditions and trends; and |
|
|
|
|
● |
departures
of any of our key employees. |
Presently,
an exchange listing of our common stock is not likely since we are
a U.S.-based company focused on the cannabis industry, which
remains illegal under federal law. Moreover, we may not be able to
attract institutional ownership of our stock or research analysts
to cover our stock in the foreseeable future.
In
the past, following periods of volatility in the market price of a
company’s securities, securities class action litigation has often
been brought against that company. Due to the potential volatility
of our stock price, we may therefore be the target of securities
litigation in the future. Securities litigation could result in
substantial costs and divert management’s attention and resources
from our business.
In
addition, if the market for stocks in our industry, or the stock
market in general, experiences a loss of investor confidence, the
market price of our common stock could decline for reasons
unrelated to our business, financial condition, or results of
operations. If any of the foregoing occurs, it could cause the
price of our common stock to fall and may expose us to lawsuits
that, even if unsuccessful, could be costly to defend and a
distraction to our Board of Directors and management.
The application of the “penny stock” rules could adversely affect
the market price of our common shares and increase an investor’s
transaction costs to sell those shares.
The
SEC has adopted Rule 3a51-1, which establishes the definition of a
“penny stock,” for the purposes relevant to us, as any equity
security that has a market price of less than $5.00 per share or
with an exercise price of less than $5.00 per share, subject to
certain exceptions. For any transaction involving a penny stock,
unless exempt, Rule 15g-9 requires:
|
● |
that
a broker or dealer approve a person’s account for transactions in
penny stocks, and |
|
|
|
|
● |
the
broker or dealer receives from the investor a written agreement to
the transaction, setting forth the identity and quantity of the
penny stock to be purchased. |
In
order to approve a person’s account for transactions in penny
stocks, the broker or dealer must:
|
● |
obtain
financial information and investment experience objectives of the
person, and |
|
|
|
|
● |
make
a reasonable determination that the transactions in penny stocks
are suitable for that person and the person has sufficient
knowledge and experience in financial matters to be capable of
evaluating the risks of transactions in penny stocks. |
The
broker or dealer must also deliver, prior to any transaction in a
penny stock, a disclosure schedule prescribed by the SEC relating
to the penny stock market, which, in highlight form:
|
● |
sets
forth the basis on which the broker or dealer made the suitability
determination, and |
|
|
|
|
● |
that
the broker or dealer received a signed, written agreement from the
investor prior to the transaction. |
Generally,
brokers may be less willing to execute transactions in securities
subject to the “penny stock” rules or involving the cannabis
industry. This may make it more difficult for investors to dispose
of our common stock and may cause a decline in the market value of
our stock.
Our Board of Directors is authorized to reclassify any unissued
shares of our preferred stock into one or more classes, which could
convey special rights and privileges to its
owners.
Our
articles of incorporation permit our Board of Directors to
reclassify any authorized but unissued shares of preferred stock
into one or more classes. Our Board of Directors will generally
have broad discretion over the size and timing of any such
classification, subject to a finding that the classification and
issuance of preferred stock is in our best interests. We are
authorized to issue up to 350,000,000 shares of common stock and
150,000,000 shares of preferred stock. As of December 31, 2019, we
had 228,216,638 shares of common stock issued and outstanding and
42,030,331 shares of preferred stock issued and outstanding. In the
event our Board of Directors opts to classify a portion of our
unissued shares of preferred stock into a class of preferred stock,
those preferred shares would have a preference over our common
stock with respect to dividends and liquidation. The cost of any
classification would be borne by our existing common stockholders.
The class voting rights of any preferred shares we may issue could
make it more difficult for us to take some actions that may, in the
future, be proposed by the Board of Directors and/or the holders of
our common stock, such as a merger, exchange of securities,
liquidation, or alteration of the rights of a class of our
securities, if these actions were perceived by the holders of
preferred shares as not in their best interests. These effects,
among others, could have an adverse effect on your investment in
our common stock.
Rule 144 contains risks for certain
shareholders.
From
time to time, we issue shares on an unregistered basis, which may
be eligible for resale under SEC Rule 144 promulgated under the
Securities Act. In the event there are shares outstanding that can
be sold under Rule 144, there may be market pressure on our
stock.
We do not intend to pay cash dividends on our common
stock.
We
currently are not profitable and do not expect to achieve
profitability in the foreseeable future. We have never declared or
paid dividends on our common stock. We intend to invest any
available funds to continue to grow our revenue. Accordingly, we do
not expect to pay cash dividends to our stockholders now or in the
foreseeable future.
The market price of our shares of common stock may be adversely
affected by the sale of shares by our management or large
stockholders.
Sales
of our shares of common stock by our officers or senior managers
through 10b5-1 plans or otherwise or by large stockholders could
adversely and unpredictably affect the price of our common stock.
Additionally, the price of our shares of common stock could be
affected even by the potential for sales by these persons. We
cannot predict the effect that any future sales of our common
stock, or the potential for those sales, will have on our share
price. Furthermore, due to relatively low trading volume of our
stock, should one or more large stockholders seek to sell a
significant portion of their stock in a short period of time, the
price of our stock may decline.
Item 1B. Unresolved Staff
Comments
We
are a smaller reporting company as defined by Rule 12b-2 of the
Exchange Act, and therefore we are not required to provide
information under this item.
Item 2. Properties
We
own no real property. On June 27, 2017, we executed a lease, which
became effective September 29, 2017, for our manufacturing and
office space at 1780 55th Street, Boulder, Colorado
80301. The term of the lease commenced September 29, 2017 and
continues through August 31, 2022. Our leased space is
approximately 18,600 square feet. We believe that our lease is at
market rates and that there is sufficient space available in the
Boulder, Colorado area to obtain additional or other space if and
when required.
Item 3. Legal
Proceedings
As of
December 31, 2019, there were 6,750,000 restricted stock units that
had not been settled due to a dispute with a former employee over
the required withholding taxes to be paid to us for remittance to
the appropriate tax authorities. We commenced an arbitration action
against the former employee regarding the dispute. The former
employee also made claims in the arbitration action against us for
unpaid wages. As stated in a pleading in the arbitration, on March
9, 2020, we issued the former employee 6,750,000 shares of common
stock in settlement of these restricted stock units after taking
measures to mitigate our exposure to penalties and liability for
the failure to properly withhold income taxes.
We
are not currently subject to any material legal proceedings, nor,
to our knowledge, is any material legal proceeding threatened
against us. From time to time, we may be a party to certain legal
proceedings in the ordinary course of business, including
proceedings relating to the enforcement of our rights under
contracts with our customers. While the outcome of these legal
proceedings cannot be predicted with certainty, we do not expect
that these proceedings will have a material effect upon our
financial condition or results of operations.
Item 4. Mine Safety
Disclosures
Not
applicable.
PART II
Item 5. Market for Registrant’s Common
Equity, Related Stockholder Matters and Issuer Purchases of Equity
Securities
Common
Stock
Our
shares of common stock are quoted on the OTCQB operated by The
OTCMarkets under the symbol “SRNA.” Over-the-counter market
quotations reflect inter-dealer prices, without retail mark-up,
mark-down or commission and may not necessarily represent actual
transactions.
We
have approximately 130 shareholders of record and approximately
15,400 beneficial shareholders.
Equity
Compensation Plans
On
August 1, 2017, our Board of Directors adopted and approved the
2017 Equity Incentive Plan (the “2017 Equity Plan”) in order to
attract, motivate, retain, and reward high-quality executives and
other employees, officers, directors, consultants, and other
persons who provide services to us by enabling such persons to
acquire an equity interest in us. Under the 2017 Equity Plan, our
Board of Directors may award stock options, stock appreciation
rights (“SARs”), restricted stock awards (“RSAs”), restricted stock
unit awards (“RSUs”), shares granted as a bonus or in lieu of
another award, and other stock-based performance awards. The 2017
Equity Plan allocates 50,000,000 shares of our common stock (“Plan
Shares”) for issuance of equity awards under the 2017 Equity Plan.
As of December 31, 2019, we have granted, under the 2017 Equity
Plan, awards in the form of RSAs for services rendered by
independent directors and consultants, non-qualified stock options,
RSUs and stock bonus awards.
The
information for our 2017 Equity Plan as of December 31, 2019 is
summarized as follows:
|
|
Number of
securities to be issued upon exercise of outstanding options,
warrants and rights |
|
|
Weighted-average
exercise price of outstanding options, warrants and
rights |
|
|
Number of
securities remaining available for future issuance under equity
compensation plans (excluding securities reflected in first
column) |
|
Equity
compensation plans approved by shareholders |
|
|
- |
|
|
|
- |
|
|
|
- |
|
Equity
compensation plans not approved by shareholders (1) |
|
|
11,035,000 |
|
|
$ |
0.099 |
|
|
|
21,161,182 |
|
Total |
|
|
11,035,000 |
|
|
$ |
0.099 |
|
|
|
21,161,182 |
|
(1)
The number of securities remaining available for future issuance as
of December 31, 2029 include: (i) 800,000 shares to be issued upon
vesting of outstanding RSUs, (ii) 6,750,000 shares under RSUs that
vested but were not settled with the issuance of shares until March
9, 2020 due to a dispute with a former employee over the required
withholding taxes to be paid to the Company for remittance to the
appropriate tax authorities, and (iii) the remaining Plan Shares of
13,611,182 which are available for future award under the 2017
Equity Plan.
|
Refer
to Note 14 – Equity Incentive Plan of our consolidated
financial statements, which are included as part of this Annual
Report for the further details on our 2017 Equity Plan.
Item 6. Selected Financial
Data
We
are a smaller reporting company, as defined by Rule 12b-2 of the
Exchange Act, and therefore we are not required to provide the
information under this item.
Item 7. Management’s Discussion and
Analysis of Financial Condition and Results of
Operations
The
following discussion should be read in conjunction with our
consolidated financial statements and related notes and other
financial information included elsewhere in this Annual Report,
which include additional information about our accounting policies,
practices, and the transactions underlying our financial results.
In addition to historical information, this Annual Report contain
forward-looking information that involves risks and uncertainties.
Our actual results could differ materially from those anticipated
by such forward-looking information due to the factors discussed
under “Cautionary Statements” appearing elsewhere herein and the
risks and uncertainties described or identified in “Item 1A – Risk
Factors” in this Annual Report.
Please
also refer to “Non-GAAP Financial Measures” discussed elsewhere in
this Annual Report.
The
following discussion should be read in conjunction with Item 1 –
Business in this Annual Report, and our consolidated financial
statements and accompanying notes to consolidated financial
statements included in this Annual Report. Our Management’s
Discussion and Analysis of Financial Condition and Results of
Operations (“MD&A”) is segregated into four sections,
including:
Executive Overview. This section provides a summary of our
operating performance and cash flows, industry trends and our
strategic initiatives.
Critical Accounting Policies and Estimates. This
section describes the accounting areas where management makes
critical estimates to report our financial condition and results of
operations.
Results of Operations. This section provides an
analysis of our consolidated results of operations for the two
comparative periods presented
in our consolidated financial statements.
Liquidity, Capital Resources and Financial Position.
This section provides an analysis of cash flow, contractual
obligations, and certain
other matters affecting our financial position.
Executive
Overview
Our
revenue for the year ended December 31, 2019 was $15,224,000
compared to $9,582,000 for the year ended December 31, 2018, an
increase of $5,642,000, or 59%. Overall, we had a net loss of
$1,339,000 for the year ended December 31, 2019 as compared to a
net loss of $4,744,000 for the year ended December 31, 2018, a
decrease of $3,405,000, or 72%. Our 2019 adjusted net income was
$92,000 compared to a 2018 adjusted net loss of $2,592,000. Our
adjusted net income (loss) is our GAAP net income (loss) after
addback for our non-cash equity compensation expenses, debt-related
items and depreciation expense.
We
had record quarterly revenue of $4,210,000 and $5,524,000 in Q2 and
Q3 2019, respectively, which was critical to our earning positive
net income of $140,000 and $222,000 in Q2 and Q3 2019,
respectively. However, one of the most significant financial
challenges we face is the inconsistent and unpredictable revenue we
generate quarter-over-quarter, and our revenue and cash flow remain
difficult to predict.
In late
March 2020, as a result of the heightened uncertainty relating to
the potential impacts of the coronavirus on our business operations
as well as the headwinds affecting the cannabis industry, in
particular the limited access to capital, we assessed our near-term
operations, working capital, finances and capital formation
opportunities, and implemented a downsizing of our operations and a
workforce reduction to preserve cash resources and focus our
operations on customer-centric sales and project management
activities. The duration and likelihood of success of this
downsizing effort and workforce reduction are uncertain, and there
is no assurance that we will be able to continue our operations.
Further, if our customers or prospects are unable to obtain project
financing and we are unable to increase revenues, or otherwise
generate cash flows from operations, we will not be able to
successfully execute on the various strategies and initiatives set
forth in this Annual Report to grow our business.
We
have a three-prong growth strategy.
1.
Expand our Customer Base. We have a sales and
marketing program that generates many prospect relationships.
However, our limited range of higher cost products, mostly chilled
water systems, reduces the number of customer prospects who can
afford to buy from us. This year, we will broaden our product line
to include lower- and mid-cost products, such as split systems and
packaged roof top units. We believe these new products and services
will increase our addressable market and sales, further leveraging
our investment in sales and marketing.
One
of our key 2019 goals was to obtain more business from MFOs, which
have greater financial resources, are more sophisticated, buy more
and larger systems, and are less prone to project delays and
cancellations, compared to the smaller cultivators that had been
our primary customers in the past. We enjoyed success in our MFO
outreach in 2019, booking seven projects with MFOs (three with a
single MFO), representing $8.3 million in revenue, or 55% of our
total 2019 revenue. However, we still have significant work ahead
of us to fill our sales pipeline with MFO customers that we believe
will result in more consistent and predictable revenue and cash
flow.
2.
Sell More Automation and Control Systems. We
fulfilled the first step of another key 2019 goal by launching our
SentryIQTM sensors, controls and automation (“SCA”)
platform—a turnkey, single-vendor HVAC equipment and controls
integration solution. We have entered into seven contracts with six
different companies to implement our SentryIQTM
platform—covering equipment for a combined total of over 212,000
square feet of cultivation space. These systems provide a steady
stream of data that our customers can use to make daily cultivation
decisions. Additionally, we can use this data to track trends and
apply future enhancements to our products and services, fostering
closer relationships with our customers throughout their
facilities’ life cycles. This product line is important for
tactical and strategic reasons previously discussed.
We
plan to continue to develop technology and
innovations that provide value-add to our customers. We also intend
to seek out “best-in-class” partners to help us automate and
control the indoor grow facilities of the future.
3.
Engage in Strategic Relationships with other Technology
Leaders. During 2019, we identified several business
verticals that we believe could be logical and natural complements
to our climate control business, including: lighting, fertigation
(automated process of delivering nutrients and water to plants),
benches (customized systems to optimize use of the growing space),
cultivation management technology (software), consumables (growing,
packaging, facility and lab supplies), and operational improvement
analytics (modeling, data aggregation and artificial intelligence).
We intend to work with “best-in-class” vendors to develop more
comprehensive, end-to-end, integrated solutions and specialized
products and services that can help our cultivators compete in the
market, whether through automation, software or operating
efficiencies. We hope to establish one or more strategic alliances,
such as reseller, distribution, co-marketing or product development
agreements, with select companies which are consistent with our
strategic direction.
Over time, if some of these strategic alliances are successful in
driving top-line revenue for us and our partners, such
relationships could develop into more exclusive arrangements or
evolve into possible acquisitions or a source of strategic capital
for us. There can be no assurance that we will be able to
successfully execute any of these strategic initiatives. Efforts
will be primarily focused on working with new strategic partners to
co-market each other’s products and services and possibly jointly
develop new and improved products and services with
cannabis-specific applications, as opposed to seeking
acquisitions.
*******
Our
goal for the immediate future is to grow organically,
strategically and profitably. We started 2019 with just over
$250,000 in cash but, with our discipline on cost control and our
strong sales growth, we were able to increase our cash to $922,000
at the end of 2019. We were self-sustaining during 2019, having
generated $672,000 in operating cash flows, and we did not require
any outside capital. In 2019, we exercised strict financial
discipline to achieve the goal of cash operating profitability and
cash flow sustainability.
Revenue. Our 2019 revenue was $15,224,000. Our
2019 revenue represents an increase of 59% compared to 2018.
However, one of our MFO customers accounted for 44% of our 2019
revenue. We believe, among other things, that we need to build a
diversified sales pipeline of MFOs, which we believe we will
increase our consistency and predictability of revenue.
Gross
Margin. Our 2019 gross margin was 29.9%, an increase
from 25.6% in 2018. This increase reflects a shift in our product
mix to higher margin, customized and proprietary
products.
Profitability. Our 2019 adjusted net income was
$92,000 compared to a 2018 adjusted net loss of $2,592,000. Our
adjusted net income (loss) is a key management metric and point of
focus for us because it provides a proxy for the cash we generate
from operations.
Though
improved in 2019, our working capital remains negative, and we have
limited capital resources, which are impediments to the overall
viability of our business as planned. The effect of the COVID-19
response is presenting further challenges for us in 2020. Without
increasing our current revenue and adding new sources of revenue,
we cannot predict our future. As discussed elsewhere in this Annual
Report, we have taken steps to downsize and reorient our operations
to reduce costs. We cannot predict how long our cost cutting
measures will sustain the Company or how long the current economic
situation will last.
As we
enter 2020, our backlog was $9,558,000, an increase of $1,029,000,
or 12%, from our December 31, 2018 backlog. During 2019, we had net
bookings of $16,253,000, consisting of: (i) $19,769,000 of new
sales contracts executed in 2019, (ii) $413,000 net positive
changes orders, and (iii) $3,929,000 in project
cancellations.
The
following table sets forth: (i) our beginning backlog (the
remaining contract value of outstanding sales contracts for which
we have received an initial deposit as of the previous period),
(ii) our net bookings for the period (new sales contracts executed
during the period for which we received an initial deposit, net of
any adjustments including cancelations and change orders during the
period), (iii) our recognized revenue for the period, and (iv) our
ending backlog for the period (the sum of the beginning backlog and
net bookings, less recognized revenue). Based on the current
economic climate and our cost cutting measures, there is no
assurance that we will be able to continue to obtain the level of
bookings that we have had in the past or fulfill our current
backlog, and we may experience contract cancellations, project
scope reductions or project delays.
|
|
For the
quarter ended |
|
|
|
December
31,
2018 |
|
|
March
31,
2019 |
|
|
June
30,
2019 |
|
|
September
30,
2019 |
|
|
December
31,
2019 |
|
Backlog,
beginning balance |
|
$ |
8,886,000 |
|
|
$ |
8,529,000 |
|
|
$ |
11,543,000 |
|
|
$ |
13,023,000 |
|
|
$ |
10,143,000 |
|
Net
bookings, current period |
|
$ |
1,838,000 |
|
|
$ |
4,785,000 |
|
|
$ |
5,690,000 |
|
|
$ |
2,644,000 |
|
|
$ |
3,134,000 |
|
Recognized
revenue, current period |
|
$ |
2,195,000 |
|
|
$ |
1,771,000 |
|
|
$ |
4,210,000 |
|
|
$ |
5,524,000 |
|
|
$ |
3,719,000 |
|
Backlog,
ending balance |
|
$ |
8,529,000 |
|
|
$ |
11,543,000 |
|
|
$ |
13,023,000 |
|
|
$ |
10,143,000 |
|
|
$ |
9,558,000 |
|
As
has historically been the case at each quarter-end, there remains
significant uncertainty regarding the timing of revenue recognition
of our backlog as of December 31, 2019. As of December 31, 2019,
$5,903,000 of our backlog, or 62%, was attributable to customer
contracts for which we have only received an initial advance
payment to cover our engineering services (“engineering only paid
contracts”). There are always risks that the equipment portion of
our engineering only paid contracts will not be completed or will
be delayed, which could occur if the customer is dissatisfied with
the quality or timeliness of our engineering services, there is a
delay or abandonment of the project due to the customer’s inability
to obtain project financing or licensing, or the customer
determines not to proceed with the project due to economic factors,
such as declining cannabis wholesale prices in the
state.
We
have provided an estimate in our consolidated financial statements
for when we expect to recognize revenue on our remaining
performance obligations (i.e., our Q4 2019 backlog), using separate
time bands, with respect to engineering only paid contracts and
partial equipment paid contracts. However, there continues to be
significant uncertainty regarding the timing of our recognition of
revenue on our Q4 2019 backlog. Refer to the Revenue
Recognition section of Note 2 in our consolidated financial
statements, included as part of this Annual Report for additional
information on our estimate of future revenue recognition on our
remaining performance obligations.
Our
backlog, remaining performance obligations and net bookings may not
be indicative of future operating results, and our customers may
attempt to renegotiate or terminate their contracts for a number of
reasons, including delays in or inability to obtain project
financing or licensing or abandonment of the project entirely.
Accordingly, there can be no assurance that contracts included in
backlog or remaining performance obligations will actually generate
revenues or when the actual revenues will be generated. Net
bookings and backlog are considered non-GAAP financial measures,
and therefore, they should be considered in addition to, rather
than as a substitute for, our GAAP measures for recognized revenue,
deferred revenue and remaining performance obligations. Further, we
can provide no assurance as to the profitability of our contracts
reflected in remaining performance obligations, backlog and net
bookings.
Critical
Accounting Policies and Estimates
This
discussion and analysis of our financial condition and results of
operations is based upon our consolidated financial statements,
which have been prepared in conformity with accounting principles
generally accepted in the United States of America. Certain
accounting policies are particularly important to the understanding
of our financial position and results of operations and require the
application of significant judgment by our management or can be
materially affected by changes from period to period in economic
factors or conditions that are outside of our control. As a result,
they are subject to an inherent degree of uncertainty. In applying
these policies, management uses their judgment to determine the
appropriate assumptions to be used in the determination of certain
estimates. Those estimates are based on our historical operations,
our future business plans and projected financial results, the
terms of existing contracts, observance of trends in the industry,
information provided by our customers, and information available
from other outside sources, as appropriate. Actual results could
materially differ from those estimates. For information regarding
our critical accounting policies as well as recent accounting
pronouncements, see Note 2 of our consolidated financial
statements.
Our
management has discussed the development and selection of critical
accounting estimates with the Audit Committee of the Board of
Directors and the Audit Committee has reviewed our disclosure
relating to critical accounting estimates in this Annual Report. We
believe the following are the more significant judgments and
estimates used in the preparation of our consolidated financial
statements.
Allowance
for accounts receivable. Accounts receivables are recorded at
the invoiced amount, or based on revenue earned for items not yet
invoiced, and generally do not bear interest. An allowance for
doubtful accounts is established, as necessary, based on past
experience and other factors, which, in management’s judgment,
deserve current recognition in estimating bad debts. Based on its
review, we establish or adjust the allowance for specific customers
and the accounts receivable portfolio as a whole. As of December
31, 2019 and 2018, the allowance for doubtful accounts was $151,673
and $119,022, respectively. If the financial condition of our
customers were to deteriorate, resulting in an impairment of their
ability to make payments, additional allowances may be
required.
Excess
and obsolete inventory. Inventory is stated at the lower of
cost or net realizable value. The inventory is valued based on a
first-in, first-out (“FIFO”) basis. Lower of cost or net realizable
value is evaluated by considering obsolescence, excessive levels of
inventory, deterioration and other factors. Adjustments to reduce
the cost of inventory to its net realizable value, if required, are
made for estimated excess, obsolescence or impaired inventory.
Excess and obsolete inventory is charged to cost of revenue and a
new lower-cost basis for that inventory is established and
subsequent changes in facts and circumstances do not result in the
restoration or increase in that newly established cost basis. As of
December 31, 2019 and 2018, the allowance for excess and obsolete
inventory was $71,376 and $295,347, respectively.
Goodwill
impairment. Goodwill, defined as unidentified asset(s) acquired
in conjunction with a business acquisition, is tested for
impairment on an annual basis and between annual tests whenever
events or changes in circumstances indicate that the carrying
amount may not be recoverable. We recorded goodwill in connection
with our acquisition of Hydro in July 2014. We perform a
quantitative impairment test annually during the fourth quarter by
comparing the fair value of the reporting unit with its carrying
amount, including goodwill. If the fair value of the reporting unit
exceeds its carrying amount, goodwill is considered not impaired.
An impairment charge would be recognized for the amount by which
the carrying amount exceeds the reporting unit’s fair value. We
completed this assessment as of December 31, 2019, and concluded
that no impairment existed.
Product
warranty. We warrant the products that we manufacture for a
warranty period equal to the lesser of 12 months from start-up or
18 months from shipment. Our warranty provides for the repair,
rework, or replacement of products (at our option) that fail to
perform within stated specification. Our third-party suppliers also
warrant their products under similar terms, which are
passed-through to our customers. We assess the historical warranty
claims on our manufactured products and, since 2016, warranty
claims have been approximately 1% of annual revenue generated on
these products. We continue to assess the need to record a warranty
reserve at the time of sale based on historical claims and other
factors. As of December 31, 2019 and 2018, we had an accrued
warranty reserve amount of $185,234 and $144,822, respectively,
which are included in accounts payable and accrued liabilities on
our consolidated balance sheets.
Income
taxes. We account for deferred tax liabilities and assets for
the future consequences of events that have been recognized in our
consolidated financial statements or tax returns. Measurement of
the deferred items is based on enacted tax laws. In the event the
future consequences of differences between financial reporting
bases and tax bases of our assets and liabilities result in a
deferred tax asset, we perform an evaluation of the probability of
being able to realize the future benefits indicated by such asset.
A valuation allowance related to a net deferred tax asset is
recorded when it is more likely than not that some portion or all
of the net deferred tax asset will not be realized. Management’s
judgment is required in determining our provision for income taxes,
deferred tax assets and liabilities, and any valuation allowance
recorded against the net deferred tax assets. We recorded a full
valuation allowance as of December 31, 2019 and 2018. Based on the
available evidence, we believe it is more likely than not that we
will not be able to utilize our net deferred tax assets in the
foreseeable future. We intend to maintain valuation allowances
until sufficient evidence exists to support the reversal of such
valuation allowances. We make estimates and judgments about our
future taxable income that are based on assumptions that are
consistent with our plans. Should the actual amounts differ from
our estimates, the carrying value of our deferred tax assets could
be materially impacted.
Share-based
compensation. We recognize the cost resulting from all
share-based compensation arrangements, including stock options,
restricted stock awards and restricted stock units that we grant
under our equity incentive plan in our consolidated financial
statements based on their grant date fair value. The expense is
recognized over the requisite service period or performance period
of the award. The service inception date is typically the grant
date, but the service inception date may be prior to the grant
date. Awards with a graded vesting period based on service are
expensed on a straight-line basis for the entire award. Awards with
performance-based vesting conditions which require the achievement
of a specific company financial performance goal at the end of the
performance period and required service period are recognized over
the performance period. Each reporting period, we reassess the
probability of achieving the respective performance goal. If the
goals are not expected to be met, no compensation cost is
recognized and any previously recognized amount recorded is
reversed. If the award contains market-based vesting conditions,
the compensation cost is based on the grant date fair value and
expected achievement of market condition and is not subsequently
reversed if it is later determined that the condition is not likely
to be met or is expected to be lower than initially expected. The
grant date fair value of stock options is based on the
Black-Scholes Model. The Black-Scholes Model requires judgmental
assumptions including volatility and expected term, both based on
historical experience. The risk-free interest rate is based on U.S.
Treasury interest rates whose term is consistent with the expected
term of the option.
Allocation
of transaction price; standalone selling price. A contract’s
transaction price is allocated to each distinct performance
obligation and recognized as revenue when, or as, the performance
obligation is satisfied. When there are multiple performance
obligations within a contract, we allocate the transaction price to
each performance obligation based on standalone selling price. We
determine the standalone selling price for each of the performance
obligations at the inception of the contract and do not adjust the
initial allocation for future changes in any selling prices. When
estimating the selling price, we use various observable inputs. The
best observable input is our actual selling price for the same good
or service, however, this input is generally not available for our
contracts containing multiple performance obligations. For
engineering services, we estimate the standalone selling price by
reference to certain physical characteristics of the project, such
as facility size and mechanical systems involved, which are
indicative of the scope and complexity of the mechanical
engineering services to be provided. For equipment sales, the
standalone selling price is determined by forecasting the expected
costs of the equipment and then adding an appropriate margin, based
on a range of acceptable margins established by management.
Depending on the nature of the performance obligations, we may use
a combination of different methods and observable inputs if certain
performance obligations have highly variable or uncertain
standalone selling prices. Once the selling prices are determined,
we apply the relative values to the total contract consideration
and estimates the amount of the transaction price to be recognized
as each promise is fulfilled.
Remaining
performance obligations. The revenue standard requires certain
quantitative and qualitative disclosures about our remaining
performance obligations, which are defined as performance
obligations that are unsatisfied (or partially unsatisfied) as of
the end of the reporting period, including (i) the aggregate amount
of the transaction price allocated to the remaining performance
obligations, and (ii) when we expect to recognize as revenue with
respect to such amounts on either: (x) a quantitative basis using
appropriate time bands for the duration of the remaining
performance obligations, or (y) by using qualitative information.
Industry uncertainty, project financing concerns, and the licensing
and qualification of our prospective customers, which are out of
our control, make it difficult for us to predict when we will
recognize revenue on our remaining performance obligations. There
are risks that we may not realize the full contract value on
customer projects in a timely manner or at all, and completion of a
customer’s cultivation facility project is dependent upon the
customer’s ability to secure funding and real estate, obtain a
license and then build their cultivation facility so they can take
possession of the equipment. Accordingly, the time it takes for
customers to complete a project, which corresponds to when we are
able to recognize revenue, is driven by numerous factors including:
(i) the large number of first-time participants interested in the
indoor cannabis cultivation business; (ii) the complexities and
uncertainties involved in obtaining state and local licensure and
permitting; (iii) local and state government delays in approving
licenses and permits due to lack of staff or the large number of
pending applications, especially in states where there is no cap on
the number of cultivators; (iv) the customer’s need to obtain
cultivation facility financing; (v) the time needed, and
coordination required, for our customers to acquire real estate and
properly design and build the facility (to the stage when climate
control systems can be installed); (vi) the large price tag and
technical complexities of the climate control and air sanitation
system; (vii) the availability of power; and (viii) delays that are
typical in completing any construction project.
There
is significant uncertainty regarding the timing of our recognition
on all remaining performance obligations as of December 31, 2019.
Customer contracts for which we have only received an initial
advance payment to cover the allocated value of our engineering
services (“engineering only paid contracts”) carry enhanced risks
that the equipment portion of these contracts will not be completed
or will be delayed, which could occur if the customer is
dissatisfied with the quality or timeliness of our engineering
services or there is a delay or abandonment of the project due to
the customer’s inability to obtain project financing or licensing.
In contrast, after the customer has made an advance payment for a
portion of the equipment to be delivered under the contract
(“partial equipment paid contracts”), we are typically better able
to estimate the timing of revenue recognition since the risks and
delays associated with licensing, permitting and project funding
are typically mitigated once the initial equipment payment is
received.
Commitments
and contingencies. In the normal course of business, we are
subject to loss contingencies, such as legal proceedings and claims
arising out of our business, that cover a wide range of matters,
including, among others, customer disputes, government
investigations and tax matters. An accrual for a loss contingency
is recognized when it is probable that an asset had been impaired
or a liability had been incurred and the amount of loss can be
reasonably estimated.
Results
of Operations
Comparison of Years ended December 31, 2019 and
2018
Revenues
and Cost of Goods Sold
Revenue
for the year ended December 31, 2019 was $15,224,000 compared to
$9,582,000 for the year ended December 31, 2018, an increase of
$5,642,000, or 59%. This revenue increase was partly the result of
our increased net bookings in 2019, which grew from $13,700,000 in
2018 to $16,300,000 in 2019, or 19%. However, despite our increases
in 2019 bookings and revenue, we remain unable to consistently
convert our backlog into revenue on a quarter-over-quarter basis.
Our revenue conversion is largely dependent on customer-centric
factors—outside of our control—such as industry uncertainty,
project financing concerns, and the licensing and qualification of
our prospective customers, which makes it difficult for us to
predict when we will recognize revenue on our backlog.
Our
2019 revenue included seven projects with MFOs totaling $8,324,000.
These seven projects consisted of the following project types:
three new build, three expansion and one retrofit. Two of these
expansion projects and one retrofit project were with a single MFO,
which generated aggregate revenue of $6,700,000. These two
expansion projects also included $2,270,000 in revenue from our new
custom air handlers and $125,000 in revenue from our Sentry IQ
controls.
Cost
of revenue increased by $3,544,000 from $7,132,000 for the year
ended December 31, 2018 to $10,676,000 for the year ended December
31, 2019.
The
gross profit for the year ended December 31, 2019 was $4,549,000
compared to $2,450,000 for the year ended December 31, 2018. Gross
profit margin increased by approximately four percentage points
from 25.6% for the year ended December 31, 2018 to 29.9% for the
year ended December 31, 2019. This increase was primarily due to
lower salaries and benefits, lower project management costs and a
decrease in shipping and handling expense offset by higher outside
engineering and warranty expenses.
Our
revenue cost structure is comprised of both fixed and variable
components. The fixed cost component represents engineering,
manufacturing and project management salaries and benefits and
manufacturing overhead that totaled $1,426,000, or 9.4% of total
revenue, for the year ended December 31, 2019 as compared to
$1,666,000, or 17.4% of total revenue, for the year ended December
31, 2018. The decrease of $240,000 was primarily due to a decrease
in salaries and benefits of $238,000. The variable cost component,
which represents our cost of equipment, outside engineering costs,
shipping and handling, travel and warranty costs, totaled
$9,250,000, or 60.8% of total revenue, in the year ended December
31, 2019 as compared to $5,466,000, or 57.0% of total revenue, in
the year ended December 31, 2018. In the year ended December 31,
2019 as compared to the prior year: (i) our outside engineering
costs increased by $230,000, (ii) our warranty costs increased by
$201,000, which were offset by (iii) a reduction in shipping and
handling costs of $49,000 and (iv) decreased travel of
$19,000.
Operating
Expenses
Operating
expenses decreased by 19% from $7,270,000 for the year ended
December 31, 2018 to $5,859,000 for the year ended December 31,
2019, a decrease of $1,411,000. The operating expense decrease
consisted primarily of: (i) a decrease in selling, general and
administrative expenses (“SG&A expenses”) of $1,310,000, (ii) a
decrease in advertising and marketing expenses of $304,000, offset
by (iii) an increase in product development expenses of
$203,000.
The
decrease in SG&A expenses for the year ended December 31, 2019
compared to the year ended December 31, 2018, was due primarily to:
(i) a decrease of $795,000 in stock-based compensation, (ii) a
decrease of $453,000 in salaries and benefits, (iii) a decrease in
accounting fees of $136,000, (iv) a decrease of $117,000 in travel,
(v) a decrease of $50,000 in facilities and office supplies, offset
by (vi) an increase of $96,000 in loss on asset disposal, (vii) an
increase of $85,000 in commissions and (viii) an increase of
$43,000 in investor relations costs.
The
decrease in marketing expenses were due primarily to: (i) a
decrease of $251,000 for industry trade shows and events, (ii) a
decrease in salaries and benefits of $38,000, (iii) a decrease of
$44,000 in collateral and other marketing expenses, (iv) a decrease
of $20,000 in travel, offset by (v) an increase of $26,000 for
stock based compensation and (vi) an increase of $15,000 for
outside marketing services.
Operating
Loss
We
had an operating loss of $1,311,000 for the year ended December 31,
2019, as compared to an operating loss of $4,820,000 for the year
ended December 31, 2018, a decrease of $3,509,000, or 73%. The
operating loss included $1,277,000 of non-cash, stock-based
compensation expenses and $154,000 for depreciation and
amortization in the year ended December 31, 2019 as compared to
$2,017,000 for stock-based compensation and $156,000 of
depreciation and amortization for the year ended December 31, 2018.
Excluding these non-cash items, our operating loss decreased by
$2,767,000.
Other
Income (Expense)
Our
other expenses (net) increased by $105,000 from other income (net)
of $77,000 for the year ended December 31, 2018 to other expense
(net) of $28,000 for the year ended December 31, 2019. This
increase in other expenses (net) is primarily related to: (i) our
equipment lease with a cultivation facility affiliated with one of
our Co-Founders for which we recorded $49,000 of income in 2018 and
$37,000 of expense in 2019, and (ii) our change in derivative
liability for which we recorded a gain of $21,000 in
2018.
Net
Loss
Overall,
we had a net loss of $1,339,000 for the year ended December 31,
2019 as compared to a net loss of $4,744,000 for the year ended
December 31, 2018, a decrease of $3,405,000. The net loss included
$1,277,000 of non-cash, stock-based compensation costs and
depreciation and amortization expense of $154,000 in the year ended
December 31, 2019 as compared to non-cash, stock-based compensation
expense of $2,017,000, depreciation and amortization of $156,000
and debt related income of $21,000 in the year ended December 31,
2018. Excluding these non-cash items, our net loss decreased by
$2,684,000.
Comparison of Years ended December 31, 2018 and
2017
Revenues
and Cost of Goods Sold
Revenue
for the year ended December 31, 2018 was $9,582,000 compared to
$7,210,000 for the year ended December 31, 2017, an increase of
$2,372,000, or 33%. This revenue increase was partly the result of
our increased net bookings in 2018, which grew from $9,000,000 in
2017 to $13,700,000 in 2018, or 51%. However, despite our increases
in 2018 bookings and revenue, we remain unable to consistently
convert our backlog into revenue on a quarter-over-quarter basis.
Our revenue conversion is largely dependent on customer-centric
factors – outside of our control – such as industry uncertainty,
project financing concerns, and the licensing and qualification of
our prospective customers, which makes it difficult for us to
predict when we will recognize revenue on our backlog. Cost of
revenue increased by $1,832,000 from $5,300,000 for the year ended
December 31, 2017 to $7,132,000 for the year ended December 31,
2018.
The
gross profit for the year ended December 31, 2018 was $2,450,000
compared to $1,910,000 for the year ended December 31, 2017. Gross
profit margin decreased by approximately one percentage point from
26.5% for the year ended December 31, 2017 to 25.6% for the year
ended December 31, 2018. This decrease was due primarily to higher
project management costs which were partially offset by increased
margin on our engineering services.
Our
revenue cost structure is comprised of both fixed and variable
components. The fixed cost component represents engineering,
manufacturing and project management salaries and benefits and
manufacturing overhead that totaled $1,666,000, or 17.4% of total
revenue, for the year ended December 31, 2018 as compared to
$1,205,000, or 16.7% of total revenue, for the year ended December
31, 2017. The increase of $461,000 was primarily due to an increase
in salaries and benefits of $412,000 and stock-based compensation
of $25,000. The variable cost component, which represents our cost
of equipment, outside engineering costs, shipping and handling,
travel and warranty costs, totaled $5,466,000, or 57.0% of total
revenue, in the year ended December 31, 2018 as compared to
$4,095,000, or 56.8% of total revenue, in the year ended December
31, 2017. In the year ended December 31, 2018 as compared to the
prior year: (i) our travel costs increased by $76,000, (ii) our
warranty costs increased by $29,000, which were offset by (iii) a
reduction in charges for excess and obsolete inventory allowances
of $278,000.
Operating
Expenses
Operating
expenses increased by 18% from $6,152,000 for the year ended
December 31, 2017 to $7,270,000 for the year ended December 31,
2018, an increase of $1,118,000. The operating expense increase
consisted primarily of: (i) an increase in SG&A expenses of
$766,000, and (ii) an increase in advertising and marketing
expenses of $354,000.
The
increase in SG&A expenses for the year ended December 31, 2018
compared to the year ended December 31, 2017, was due primarily to:
(i) an increase of $300,000 in salaries and benefits, (ii) an
increase of $202,000 in stock-based compensation, (iii) an increase
in consulting fees of $368,000, of which $260,000 was related to
stock-based consulting fees, (iv) an increase of $132,000 in
accounting fees, (v) an increase of $129,000 in bad debt expense,
(vi) an increase of $119,000 in depreciation offset by (vii) a
decrease of $187,000 in legal fees, and (viii) a decrease of
$576,000 in stock-based compensation to our independent
directors.
The
increase in marketing expenses were due primarily to: (i) an
increase of $320,000 for industry trade shows and events, (ii) an
increase in advertising and marketing of $83,000 offset by (iii) a
decrease of $105,000 for web development and collateral
materials.
Operating
Loss
We
had an operating loss of $4,820,000 for the year ended December 31,
2018, as compared to an operating loss of $4,242,000 for the year
ended December 31, 2017, an increase of $578,000. The operating
loss included $2,017,000 of non-cash, stock-based compensation
expenses in the year ended December 31, 2018 as compared to
$2,140,000 for the year ended December 31, 2017. Excluding these
non-cash items, our operating loss increased by
$701,000.
Other
Income (Expense)
Our
other expenses (net) decreased by $754,000 from an expense of
$677,000 for the year ended December 31, 2017 to income of $77,000
for the year ended December 31, 2018. This decrease is primarily
related to the loss on extinguishment of debt of $643,000 related
to the conversion of certain notes during 2017.
Net
Loss
Overall,
we had a net loss of $4,744,000 for the year ended December 31,
2018 as compared to a net loss of $4,919,000 for the year ended
December 31, 2017, a decrease of $175,000. The net loss included
$2,017,000 of non-cash, stock-based compensation costs and non-cash
debt-related gains of $21,000 in the year ended December 31, 2018
as compared to non-cash, stock-based compensation expense of
$2,140,000 and non-cash debt-related costs of $681,000 in the year
ended December 31, 2017. Excluding these non-cash items, our net
loss increased by $650,000.
Liquidity,
Capital Resources and Financial Position
Cash and Cash Equivalents
As of
December 31, 2019, we had cash and cash equivalents of $922,000,
compared to cash and cash equivalents of $253,000 as of December
31, 2018, an increase of 264%. The $669,000 increase in cash and
cash equivalents during the year ended December 31, 2019 was
primarily the result of cash provided by our operating activities.
Our cash is held in bank depository accounts in certain financial
institutions. We currently have deposits in financial institutions
that exceed the federally insured amount.
As of
December 31, 2019, we had accounts receivable (net of allowance for
doubtful accounts) of $138,000, inventory (net of excess and
obsolete allowance) of $1,231,000, and prepaid expenses and other
of $269,000 (including $164,000 in advance payments on inventory
purchases). While we typically require advance payment before we
commence engineering services or ship equipment to our customers,
we have made exceptions requiring us to record accounts receivable,
which carry a risk of non-collectability especially since most of
our customers are funded on an as-needed basis to complete facility
construction. We expect our exposure to accounts receivable risk to
increase as we pursue larger projects.
As of
December 31, 2019, we had no indebtedness, total accounts payable
and accrued liabilities of $1,833,000, deferred revenue of
$1,445,000, accrued equity compensation of $503,000, and the
current portion of operating lease liability of $218,000. As of
December 31, 2019, we had a working capital deficit of $1,437,000,
compared to a working capital deficit of $1,031,000 as of December
31, 2018. However, our 2019 year-end working capital deficit
includes $503,000 of accrued compensation expense that was paid in
stock options in Q1 2020. Excluding the accrued compensation
expense, the 2019 year-end working capital deficit was
$934,000.
We
have never declared or paid any cash dividends on our common stock.
We currently intend to retain all available funds and any future
earnings for use in the operation and expansion of our business and
do not anticipate paying any cash dividends in the foreseeable
future.
Because of
the current economic situation that developed during the first
quarter of 2020, we cannot predict the continuing level of working
capital that we will have in the future. Additionally, we cannot
predict that our future financial position will not deteriorate due
to cancelled or delayed contract fulfillment, reduced sales and our
ability to perform our contracts.
Summary of Cash Flows
The
following summarizes our cash flows for the years ended December
31, 2019 and 2018:
|
|
For the
Years Ended
December
31,
|
|
|
|
2019 |
|
|
2018 |
|
Net cash
provided by (used in) operating activities |
|
$ |
672,000 |
|
|
$ |
(2,849,000 |
) |
Net cash
used in investing activities |
|
|
(3,000 |
) |
|
|
(182,000 |
) |
Net cash
provided by financing activities |
|
|
- |
|
|
|
816,000 |
|
Net
increase (decrease) in cash |
|
$ |
669,000 |
|
|
$ |
(2,215,000 |
) |
Operating Activities
We
incurred a net loss for the year ended December 31, 2019 of
$1,339,000 compared to a net loss for the year ended December 31,
2018 of $4,744,000. We had an accumulated deficit of $25,685,000 as
of December 31, 2019.
Cash
provided by operations for the year ended December 31, 2019 was
$672,000 compared to cash used in operations of $2,849,000 for the
year ended December 31, 2018, a decrease in cash usage of
$3,521,000. The reduced cash usage was primarily attributable to:
(i) a decrease in cash usage resulting from a reduction in our net
loss of $3,405,000, and a change in working capital of $1,419,000,
offset by (ii) an increase in cash usage resulting from a non-cash
charges of $1,303,000. During the year ended December 31, 2019,
significant non-cash items included: (i) stock-related compensation
of $789,000, (ii) depreciation and amortization expense of
$161,000, and (iii) a loss on disposal of assets of
$115,000.
Investing Activities
Cash
used in investing activities for the year ended December 31, 2019
was $3,000, compared to cash used in investing activities of
$182,000 for the year ended December 31, 2018. During the year
ended December 31, 2018, we had payments for property and equipment
of $261,000, primarily related to leasehold improvements, offset by
proceeds from the payment of $100,000 in the tenant improvement
allowances on our building lease.
Financing Activities
Cash
provided by financing activities for the year ended December 31,
2019 was $0, compared to cash provided by financing activities of
$816,000 for the year ended December 31, 2018. During the year
ended December 31, 2018, we received $1,210,000 from a private
placement of common stock and warrants and $18,000 from the
exercise of options and warrants, which was offset by payment of
$400,000 for the repurchase of common stock from a related party,
$5,000 to purchase an option to purchase preferred stock held by a
related party, and $7,000 on a note to a related party.
Going Concern
Our
consolidated financial statements for the year ended December 31,
2019 have been presented on a going concern basis, which
contemplates the realization of assets and the satisfaction of
liabilities in the normal course of business. Our independent
registered public accounting firm included in its audit opinion on
our consolidated financial statements for the year ended December
31, 2019, a statement that there is substantial doubt as to our
ability to continue as a going concern. Our consolidated financial
statements for the year ended December 31, 2019 were prepared
assuming that we would continue as a going concern. We have
determined that our ability to continue as a going concern is
dependent on raising additional capital to fund our operations and
ultimately on generating future profitable operations. There can be
no assurance that we will be able to raise sufficient additional
capital or eventually have positive cash flow from operations to
address all of our cash flow needs. If we are not able to generate
positive cash flow from operations or find alternative sources of
cash, our business and shareholders will be materially and
adversely affected.
In late
March 2020, as a result of the heightened uncertainty relating to
the potential impacts of the coronavirus on our business operations
as well as the headwinds affecting the cannabis industry, in
particular the limited access to capital, we assessed our near-term
operations, working capital, finances and capital formation
opportunities, and implemented, a downsizing of our operations and
workforce reduction to preserve cash resources and focus our
operations on customer-centric sales and project management
activities. The duration and likelihood of success of this
workforce reduction are uncertain. If this downsizing effort does
not meet our expectations, or additional capital is not available,
we may not be able to continue our operations. Other factors that
will affect our ability to continue operations include the market
demand for our products and services, our ability to service the
needs of our customers and prospects with a reduced workforce,
management of our working capital, the availability of cash to fund
our operations, and the continuation of normal payment terms and
conditions for purchase of our products. The extent to which the
coronavirus will impact our business and our financial results will
depend on future developments, which are uncertain and cannot be
predicted at this time.
The
foregoing factors raise substantial doubt about our ability to
continue as a going concern for a period of one year from the date
our consolidated financial statements are issued. Our consolidated
financial statements do not include any adjustment that might
result from the outcome of this uncertainty.
Capital Raising
We
believe our cash balances and cash flow from operations will be
insufficient to fund our operations for the next 12 months. If we
are unable to increase revenues or otherwise generate cash flows
from operations, we will need to raise additional funding to
continue as a going concern. Based on management’s estimate for our
operational cash requirements, during the first quarter of 2020, we
took steps to downsize and reorient our operations to reduce costs.
We will need to obtain financing in order to continue our
operations and achieve our growth strategies. There can be no
assurance that we will be able to raise the necessary financing,
when and if needed, on acceptable terms or at all. If our operating
results do not meet management’s expectations, or additional
capital is not available, management believes it can downsize or
reorient operations to reduce certain expenditures. The precise
amount and timing of our financing needs cannot be determined
accurately at this time, and will depend on a number of factors,
including the market demand for our products and services,
management of working capital, and continuation of normal payment
terms and conditions for purchase of our products and
services.
We were successful in increasing our 2019 revenue and cash position
by $5,642,000 and $669,000, respectively, compared to 2018. While
we can point to several positive developments in 2019, there is
significant work ahead for us to execute on our growth plan and
achieve fiscal self-sustainability. Our working capital remains
negative and our first quarter revenue has been historically weak,
which could present further challenges for us. Without increasing
our current revenue or adding new sources of revenue, we will
likely have to further downsize our operations to reduce costs.
While our vendors have been accommodating in the past, we may not
be able to count on their continued support and they may elect to
restrict our credit terms.
Inflation
In
the opinion of management, inflation has not and will not have a
material effect on our operations in the immediate future.
Management will continue to monitor inflation and evaluate the
possible future effects of inflation on our business and
operations.
Contractual Payment Obligations
Refer
to Note 4 – Leases of our consolidated financial statements,
which are included as part of this Annual Report for the further
details on our obligations under a lease for our manufacturing and
office space.
Commitments
and Contingencies
Litigation
As of
December 31, 2019, there were 6,750,000 restricted stock units that
had not been settled due to a dispute with a former employee over
the required withholding taxes to be paid to us for remittance to
the appropriate tax authorities. We commenced an arbitration action
against the former employee regarding the dispute. The former
employee also made claims in the arbitration action against us for
unpaid wages. As stated in a pleading in the arbitration, on March
9, 2020, we issued the former employee 6,750,000 shares of common
stock in settlement of these restricted stock units after taking
measures to mitigate our exposure to penalties and liability for
the failure to properly withhold income taxes.
From
time to time, in the normal course of our operations, we are
subject to litigation matters and claims. Litigation can be
expensive and disruptive to normal business operations. Moreover,
the results of complex legal proceedings are difficult to predict
and our view of these matters may change in the future as the
litigation and events related thereto unfold. An unfavorable
outcome to any legal matter, if material, could have an adverse
effect on our operations or our financial position, liquidity or
results of operations.
Other Commitments
In
the ordinary course of business, we may provide indemnifications of
varying scope and terms to customers, vendors, lessors, business
partners, and other parties with respect to certain matters,
including, but not limited to, losses arising out of our breach of
such agreements, services to be provided by us, or from
intellectual property infringement claims made by third parties. In
addition, we have entered into indemnification agreements with our
directors and certain of our officers and employees that will
require us to, among other things, indemnify them against certain
liabilities that may arise by reason of their status or service as
directors, officers, or employees. We maintain director and officer
insurance, which may cover certain liabilities arising from our
obligation to indemnify our directors and certain of our officers
and employees, and former officers, directors, and employees of
acquired companies, in certain circumstances.
Off-Balance Sheet Arrangements
We
are required to disclose any off-balance sheet arrangements that
have or are reasonably likely to have a current or future effect on
our financial condition, changes in financial condition, revenues
or expenses, results of operations, liquidity, capital
expenditures, or capital resources that are material to investors.
As of December 31, 2019, we had no off-balance sheet arrangements.
During 2019 and 2018, we did not engage in any off-balance sheet
financing activities.
Recent
Developments
Refer
to Note 16 - Subsequent Events of our consolidated financial
statements, included as part of this Annual Report, for the more
significant events occurring since December 31, 2019.
Item 7A. Quantitative and Qualitative
Disclosures About Market Risk
We
are a smaller reporting company, as defined by Rule 12b-2 of the
Exchange Act, therefore are not required to provide the information
under this item.
Item 8. Financial Statements and
Supplementary Data
Our
consolidated financial statements are included herein, beginning on
page F-1. The information required by this item is incorporated
herein by reference to the consolidated financial statements set
forth in Item 15. “Exhibits and Financial Statement Schedules” of
this Annual Report.
Item 9. Changes in and Disagreements
with Accountants on Accounting and Financial
Disclosure
None.
Item 9A. Controls and
Procedures
Evaluation
of Disclosure Controls and Procedures
Our
management conducted an evaluation, with the participation of our
Chief Executive Officer and our Principal Financial and Accounting
Officer, which positions are currently held by the same person, of
the effectiveness of our disclosure controls and procedures (as
defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as
of the end of the period covered by this Annual Report on Form
10-K. Based upon that evaluation, our Chief Executive Officer and
our Principal Financial and Accounting Officer concluded that as a
result of the material weakness in our internal control over
financial reporting described below, our disclosure controls and
procedures were not effective as of December 31, 2019.
Management’s
Annual Report on Internal Control over Financial
Reporting
Management
is responsible for the preparation of our financial statements and
related information. Management uses its best judgment to ensure
that the financial statements present fairly, in material respects,
our financial position and results of operations in conformity with
generally accepted accounting principles.
Management
is responsible for establishing and maintaining adequate internal
control over financial reporting as defined in the Exchange Act.
These internal controls are designed to provide reasonable
assurance that the reported financial information is presented
fairly, that disclosures are adequate and that the judgments
inherent in the preparation of financial statements are reasonable.
There are inherent limitations in the effectiveness of any system
of internal controls including the possibility of human error and
overriding of controls. Consequently, an effective internal control
system can only provide reasonable, not absolute, assurance with
respect to reporting financial information.
Our
internal control over financial reporting includes policies and
procedures that: (i) pertain to maintaining records that, in
reasonable detail, accurately and fairly reflect our transactions;
(ii) provide reasonable assurance that transactions are recorded as
necessary for preparation of our financial statements in accordance
with generally accepted accounting principles and that the receipts
and expenditures of company assets are made in accordance with our
management and directors authorization; and (iii) provide
reasonable assurance regarding the prevention of or timely
detection of unauthorized acquisition, use or disposition of assets
that could have a material effect on our financial
statements.
Under
the supervision of management, by our Chief Executive Officer and
our Principal Financial and Accounting Officer, we conducted an
evaluation of the effectiveness of our internal control over
financial reporting based on the framework in Internal Control –
Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission (“COSO”) published in 2013
and subsequent guidance prepared by COSO specifically for smaller
public companies. Based on that evaluation, our management
concluded that our internal control over financial reporting was
not effective as of December 31, 2019 for the reasons discussed
below.
A
material weakness is a deficiency or a combination of deficiencies
in internal control over financial reporting such that there is a
reasonable possibility that a material misstatement of the annual
or interim consolidated financial statements will not be prevented
or detected on a timely basis.
Management
identified the following material weakness in its assessment of the
effectiveness of internal control over financial reporting as of
December 31, 2019:
The
Company did not maintain effective controls over certain aspects of
the financial reporting process because: (i) we lack a sufficient
complement of personnel with a level of accounting expertise and an
adequate supervisory review structure that is commensurate with our
financial reporting requirements, (ii) there is inadequate
segregation of duties due to the limitation on the number of our
accounting personnel, and (iii) we have insufficient controls and
processes in place to adequately verify the accuracy and
completeness of spreadsheets that we use for a variety of purposes
including revenue, taxes, stock-based compensation and other areas,
and place significant reliance on, for our financial
reporting.
We
intend to take appropriate and reasonable steps to make the
necessary improvements to remediate these deficiencies. We are
committed to continuing to improve our financial organization
including, without limitation, expanding our accounting staff and
improving our systems and controls to reduce our reliance on the
manual nature of our existing systems. However, due to our size and
our financial resources, remediating the several identified
weaknesses has not always been possible and may not be economically
feasible now or in the future.
Our
management, including our Chief Executive Officer and our Principal
Financial and Accounting Officer, does not expect that our
disclosure controls and procedures or our internal control over
financial reporting will prevent all error and all fraud. A control
system, no matter how well conceived and operated, can provide only
reasonable, not absolute, assurance that the objectives of the
control system are met. Further, the design of a control system
must reflect the fact that there are resource constraints and the
benefits of controls must be considered relative to their costs.
Due to the inherent limitations in all control systems, no
evaluation of controls can provide absolute assurance that all
control issues and instances of fraud, if any, within our Company
have been detected.
The
material weaknesses in internal control over financial reporting as
of December 31, 2019, remained unchanged from December 31, 2018.
Management believes that the material weaknesses set forth above
did not have an effect on our financial reporting for the year
ended December 31, 2019.
We
will continue to monitor and evaluate the effectiveness of our
internal control over financial reporting on an ongoing basis and
are committed to taking further action and implementing additional
enhancements or improvements, as necessary and as funds allow. We
do not, however, expect that the material weaknesses in our
disclosure controls will be remediated until such time as we have
improved our internal control over financial reporting. Subsequent
to December 31, 2019, we implemented an inventory management system
and perpetual inventory which we believe will address some of our
weaknesses.
This
Annual Report on Form 10-K does not include an attestation report
of our registered public accounting firm regarding internal control
over financial reporting. Management’s report was not subject to
attestation by our registered public accounting firm pursuant to
rules of the SEC that permit us to provide only management’s report
in this Annual Report on Form 10-K.
Changes
in Internal Control over Financial Reporting
There
were no changes identified in connection with our internal control
over financial reporting during the quarter ended December 31,
2019, that have materially affected, or are reasonably likely to
materially affect, our internal control over financial
reporting.
Item 9B. Other
Information
None.
PART III
Item 10. Directors, Executive Officers
and Corporate Governance
Information
about our Directors
Effective
November 28, 2018, pursuant to the Company’s Bylaws, the Company’s
Board of Directors (the “Board”) reduced the size of the Board from
five members to three members. The Company’s current directors are
set forth below:
Name |
|
Age |
|
Positions
& Committees |
Anthony
K. McDonald |
|
61 |
|
Director;
Chief Executive Officer and President |
Timothy
J. Keating |
|
56 |
|
Chairman
of the Board; Audit Committee |
J.
Taylor Simonton |
|
75 |
|
Director;
Audit Committee* |
|
|
|
|
|
*Chairman
of the committee |
|
|
Certain
information, as of March 23, 2020, with respect to the Company’s
current directors, including their names, a brief description of
their recent business experience, including present occupations and
employment, certain directorships that each person holds, and the
year in which each person became a director of the Company is set
forth below. The business address of each of the directors is 1780
55th Street, Boulder, Colorado 80301.
|
Name
and Year First Elected Director
|
|
Background
Information and Principal Occupation(s) During Past Five Years and
Beyond
|
|
|
|
|
|
Anthony
K. McDonald (2018) |
|
Mr.
McDonald was appointed a director on September 12, 2018. On
November 28, 2018, Mr. McDonald was appointed our Chief Executive
Officer and President. Mr. McDonald has been involved in building
businesses in the cleantech, energy efficiency and heating,
ventilation and air conditioning (“HVAC”) industries over the past
10 years. From 2008 to 2018, Mr. McDonald led sales and business
development as Vice-President—Sales for Coolerado Corp., a
manufacturer and marketer of innovative, energy-efficient air
conditioning systems for commercial, government, and military use.
Along with Coolerado’s CEO, Mr. McDonald was instrumental in
growing the business to become an INC. 600 high-growth company
award winner and assisted in raising $15 million of private funding
from a cleantech investment fund. In 2015, Coolerado was acquired
by Seeley International, Australia’s largest air conditioning
manufacturer and an innovative global leader in the design and
production of energy-efficient cooling and heating products, where
Mr. McDonald served as National Account Manager. During 2018, Mr.
McDonald was the Vice-President—Sales and an outside advisor for
SunTech Drive LLC, a solar energy equipment supplier located in
Boulder, Colorado. He is also the founder and Managing Partner of
Cleantechsell.com and the author of Cleantech Sell: The Essential
Guide To Selling Resource Efficient Products In The B2B
Market.
Prior
to joining Coolerado, Mr. McDonald spent over ten years in the
private equity industry where he was involved in numerous
transactions in the technology, manufacturing, and power
development industries. As a business development officer at
Private Capital Resource Group and MidCoast Investments, national
private equity acquisitions groups, and later as founder and
principal of Marz Capital, a specialty finance firm that provided
financing for middle market buyouts, Mr. McDonald has identified,
financed, or acquired numerous transactions with total enterprise
value in excess of $200 million.
Mr.
McDonald was also a consultant to international banks with KMPG
from 1994 to 1997 and served a as director for Keating Capital,
Inc., a publicly traded business development company that made
investments in pre-IPO companies. He previously served as a mentor
for companies in the Clean Tech Open competition.
Mr.
McDonald is a U.S. Army veteran and a graduate of the U.S. Military
Academy at West Point, N.Y. where he earned a B.S. degree in
Engineering and Economics. He also received an M.B.A. degree from
the Harvard Business School.
|
|
Timothy
J. Keating (2017) |
|
Mr.
Keating was appointed Chairman of the Board of Directors on March
14, 2017 and is a member of the Audit Committee. Mr. Keating brings
more than 34 years of Wall Street experience, including 17 years as
the principal owner of Keating Investments, LLC. Mr. Keating also
served on the Equity Capital Formation Task Force and is the
chairman of the Denver chapter of Harvard Alumni Entrepreneurs. Mr.
Keating is currently the President of Keating Wealth Management,
LLC, a Denver-area financial planning and investment advisory firm
serving high net worth investors and their families.
Mr.
Keating served as the President, Chief Executive Officer and
Chairman of the Board of Directors of Keating Capital, Inc. from
its inception in 2008 to 2015. Mr. Keating was a member of Keating
Investments, LLC from its founding in 1997 to July 1, 2014. Mr.
Keating also served as a member of the Investment Committee of
Keating Investments from 2008 to 2015. Mr. Keating served as the
President and Chief Executive Officer of Keating Investments from
its founding in 1997 to 2015. Prior to founding Keating
Investments, Mr. Keating was a proprietary arbitrage trader and
also head of the European Equity Trading Department at Bear Stearns
International Limited (London) from 1994 to 1997. From 1990 to
1994, Mr. Keating founded and ran the European Equity Derivative
Products Department for Nomura International Plc in London. Mr.
Keating began his career at Kidder, Peabody & Co., Inc. where
he was active in the Financial Futures Department in both New York
and London.
Mr.
Keating is a cum laude graduate of Harvard College with an
A.B. in Economics.
|
|
J.
Taylor Simonton (2017) |
|
Mr.
Simonton was appointed a director on May 31, 2017 and is the
chairman of the Audit Committee. Mr. Simonton spent 35 years at
PricewaterhouseCoopers, LLC (PwC), including 23 years as a partner
in the firm’s Assurance Services, before retiring in 2001. Mr.
Simonton was a partner for seven years in PwC’s National
Professional Services Group, which handles the firm’s auditing and
accounting standards, SEC, corporate governance, risk management
and quality matters. He has extensive experience with SEC filings,
including assistance with over 100 initial public offerings during
his PwC career.
In
May 2017, he was appointed an independent director, a member of the
Audit Committee (elected its Chairman in May 2018) and a member of
the Governance Committee of Master Chemical Corporation (d/b/a
Master Fluids Solutions), a private company that is a developer and
marketer of specialty chemicals. In May 2014, he was elected an
independent director and chair of the Audit Committee of Advanced
Emissions Solutions, Inc. (NASDAQ: ADES), a company which provides
environmental solutions to customers in coal-fired power
generation, municipal water and other industries primarily through
emissions and water purification control technologies. He currently
also serves as a member of the Nominating & Governance
Committee and a member of the Activated Carbon
Committee.
From
May 2008 to July 2015, Mr. Simonton served as the lead independent
director and chair of the Audit Committee of Crossroads Capital,
Inc. (f/k/a BDCA Venture, Inc. and Keating Capital, Inc.), a
publicly-traded closed-end fund regulated as a business development
company under the Investment Company Act of 1940, where he also
served as a member of the Valuation Committee which he chaired from
2008 to 2011. From October 2013 to June 30, 2018, Mr. Simonton
served as an independent director, chair of the Audit Committee and
member of the Nominating and Governance Committee of Escalera
Resources Co., a natural gas exploration and development company
(OTC: ESCR) and a member of the Compensation Committee from July
2014 to June 30, 2018.
From
October 2008 to January 2014, Mr. Simonton served as an independent
director and chair of the Audit Committee of Zynex, Inc. (OTC:
ZYXI), a company that primarily engineers, manufactures, markets
and sells its own design of electrotherapy medical devices used for
pain management and rehabilitation. Mr. Simonton served as a
director from September 2005 to May 2013 of Red Robin Gourmet
Burgers, Inc. (NASDAQ: RRGB), a casual dining restaurant chain
operator serving high quality gourmet burgers where he was a member
of the Audit Committee, of which he was chair from October 2005
until June 2009, and a member of the Nominating and Governance
Committee. From January 2003 to February 2007, he also served as a
director and the chair of the Audit Committee of Fischer Imaging
Corporation, a public company that designed, manufactured and
marketed medical imaging systems.
Mr.
Simonton served for 10 years until 2015 on the Board of Directors
of the Colorado Chapter of the National Association of Corporate
Directors (NACD), where he served over time as its Treasurer,
President, and Chairman. He is a Board Leadership Fellow, NACD’s
highest director credential, and was honored as Colorado’s 2014
Outstanding Public Company Director by the Denver Business Journal
and NACD-Colorado.
Mr.
Simonton is a 1966 graduate of the University of Tennessee -
Knoxville with a B.S. in Accounting and is a Certified Public
Accountant, licensed in Colorado.
|
Each
of the directors on our Board of Directors was elected or appointed
because he has demonstrated an ability to make meaningful
contributions to our business and affairs, has a reputation for
honesty and ethical conduct, has strong communication and
analytical skills, and has skills, experience and background that
are complementary to those of our other Board members. Mr. Keating
has extensive financing, investment banking and investor relations
experience and other managerial experience with micro- and
small-cap public companies and helping those companies define their
business strategies and implementing business plans. Mr. Simonton
has extensive financial reporting, SEC compliance and corporate
governance experience. Mr. McDonald has sales, sales and operation
management, and mergers and acquisitions experience and has been
involved in the HVAC industry for many years, with an in-depth
knowledge of climate control systems.
Director
Independence
The
Board annually determines each director’s independence, although we
are not required to have any independent directors because the
common stock of the Company is not listed on a national exchange.
We do not consider a director independent unless the Board has
determined that he has no material relationship with us. We intend
to monitor the relationships of our directors and officers through
a questionnaire each director completes no less frequently than
annually and updates periodically as information provided in the
most recent questionnaire changes.
In
order to evaluate the materiality of any such relationship, the
Board uses the definition of director independence set forth in
Rule 5605(a)(2) promulgated by the Nasdaq Stock Market. The Board
has determined that Messrs. Keating and Simonton are independent
directors. Mr. McDonald is not an independent director as a result
of his position as an executive officer.
Nominations
for Directors
The
Company has not established a nominating committee. Accordingly,
the Board is responsible for identifying individuals qualified to
serve on the Board as directors and on committees of the Board,
establishing procedures for evaluating the suitability of potential
director nominees consistent with the criteria approved by the
Board, reviewing the suitability for continued service as a
director when his or her term expires and at such other times as
the Board deems necessary or appropriate, and determining whether
or not the director should be re-nominated, and reviewing the
membership of the Board and its committees and making changes, if
any.
In
evaluating director nominees, the Board of Directors will generally
consider the following factors:
|
● |
the
appropriate size and composition of our Board of
Directors; |
|
|
|
|
● |
whether
or not the person is an “independent” director as defined in Rule
5605(a)(2) promulgated by the Nasdaq Stock Market; |
|
|
|
|
● |
the
needs of the Company with respect to the particular talents and
experience of its directors; |
|
|
|
|
● |
the
knowledge, skills and experience of nominees in light of prevailing
business conditions and the knowledge, skills and experience
already possessed by other members of the Board of
Directors; |
|
|
|
|
● |
familiarity
with national and international business matters and the
requirements of the industry in which we operate; |
|
|
|
|
● |
experience
with accounting rules and practices; |
|
|
|
|
● |
the
desire to balance the considerable benefit of continuity with the
periodic injection of the fresh perspective provided by new
members; and |
|
|
|
|
● |
all
applicable laws, rules, regulations and listing standards, if
applicable. |
There
are no stated minimum criteria for director nominees, although the
Board may consider such factors as it may deem are in the best
interests of the Company and its stockholders. The Board also
believes it is appropriate for certain key members of our
management to participate as members of the Board of
Directors.
The
Board identifies nominees by first evaluating the current members
of the Board willing to continue in service. Current members of the
Board with skills and experience that are relevant to our business
and who are willing to continue in service are considered for
re-nomination, balancing the value of continuity of service by
existing members of the Board with that of obtaining a new
perspective. If any member of the Board does not wish to continue
in service, or if the Board decides not to re-nominate a member for
re-election, the Board identifies the desired skills and experience
of a prospective director nominee in light of the criteria above,
or determines to reduce the size of the Board. Research may also be
performed to identify qualified individuals. To date, we have not
engaged third parties to identify or evaluate or assist in
identifying potential nominees, nor do we anticipate doing so in
the future.
Stockholder
Communications with Directors
Stockholders
may communicate with the Board by sending a letter to the Corporate
Secretary, Surna Inc., 1780 55th Street, Boulder, Colorado 80301.
Each communication must set forth the name and address of the
stockholder on whose behalf the communication is sent and should
indicate in the address whether the communication is intended for
the entire Board, the non-employee directors as a group or an
individual director. Each communication will be screened by the
Corporate Secretary or his designee to determine whether it is
appropriate for presentation to the Board or any specified
director(s). Examples of inappropriate communications include junk
mail, spam, mass mailings, resumes, job inquiries, surveys,
business solicitations and advertisements, as well as unduly
hostile, threatening, illegal, unsuitable, frivolous, patently
offensive or otherwise inappropriate material. Communications
determined to be appropriate for presentation to the Board, or the
director(s) to whom they are specifically addressed, will be
submitted to the Board or such director(s) on a periodic basis. Any
communications that concern accounting, internal control or
auditing matters will be handled in accordance with procedures
adopted by the Audit Committee.
Code
of Business Conduct and Ethics
Our
Board has adopted a Code of Business Conduct and Ethics, which is
available for review on our website at www.surna.com and is
also available in print, without charge, to any stockholder who
requests a copy by writing to us at Surna Inc., 1780 55th Street,
Boulder, Colorado 80301, Attention: Corporate Secretary. Each of
our directors, employees and officers, including our Chief
Executive Officer, and all of our other principal executive
officers, are required to comply with the Code of Business Conduct
and Ethics. There have not been any waivers of the Code of Business
Conduct and Ethics relating to any of our executive officers or
directors in the past year.
Meetings
and Committees of the Board
Our
Board is responsible for overseeing the management of our business.
We keep our directors informed of our business at meetings and
through reports and analyses presented to the Board and the
committees of the Board. Regular communications between our
directors and management also occur outside of formal meetings of
the Board and committees of the Board.
Meeting
Attendance
Our
Board generally holds meetings on a quarterly basis, but may hold
additional meetings as required. In 2019, the Board held six
meetings. Each of our directors attended 100% of the Board meetings
that were held during the periods when he was a director and 100%
of the meetings of each committee of the Board on which he served
that were held during the periods that he served on such committee.
We do not have a policy requiring that directors attend our annual
meetings of stockholders. We did not hold a 2019 annual meeting of
stockholders.
Committees
of the Board of Directors
Our
Board established an Audit Committee on May 31, 2017. The Audit
Committee operates pursuant to a charter approved by the Board, a
copy of which is available on our website at www.surna.com
by written request to the Company at Surna Inc., 1780 55th Street,
Boulder, Colorado 80301, Attention: Corporate Secretary. The
charter sets forth the responsibilities of the Audit Committee. The
Audit Committee’s responsibilities include recommending the
selection of our independent registered public accounting firm;
evaluating the appointment, compensation and retention of our
registered public accounting firm; receiving formal written
statements from our independent registered public accounting firm
regarding its independence, including a delineation of all
relationships between it and the Company; reviewing with such
independent registered public accounting firm the planning, scope
and results of their audit of our financial statements;
pre-approving the fees for services performed; reviewing with the
independent registered public accounting firm the adequacy of
internal control systems; reviewing our annual financial statements
and periodic filings, and receiving our audit reports and financial
statements. In addition, the Audit Committee’s responsibilities
include considering the effect on the Company of any changes in
accounting principles or practices proposed by management or the
independent registered public accounting firm, any changes in
service providers, such as the accountants, that could impact the
Company’s internal control over financial reporting, and any
changes in schedules (such as fiscal or tax year-end changes) or
structures or transactions that required special accounting
activities, services or resources. The Audit Committee is presently
comprised of two persons: Messrs. Keating and Simonton. Each member
of the Audit Committee is considered independent under the rules
promulgated by the Nasdaq Stock Market. Our Board has determined
that Mr. Simonton is an “audit committee financial expert” as that
term is defined under Item 407 of Regulation S-K of the Securities
Act of 1933, as amended (the “Securities Act”). Mr. Simonton
currently serves as Chairman of the Audit Committee. The Audit
Committee held five meetings during 2019.
Board
Leadership Structure
The
Board may, but is not required to, select a Chairman of the Board
who presides over the meetings of the Board and meetings of the
stockholders and performs such other duties as may be assigned to
him by the Board. The positions of Chairman of the Board and Chief
Executive Officer may be filled by one individual or two different
individuals. Currently the positions of Chairman of the Board and
Chief Executive Officer are separated. Our Board believes that this
structure has allowed Mr. McDonald, Chief Executive Officer, to
focus on our day-to-day business, while allowing Mr. Keating, our
Chairman of the Board, to lead the Board in its fundamental role of
providing advice to and independent oversight (including risk
oversight) of management.
Our
separated Chairman of the Board and Chief Executive Officer
positions are augmented by our independent directors, who comprise
all of our Board committees and meet regularly in executive session
without Mr. McDonald or other members of our management present to
ensure that our Board maintains an appropriate level of independent
oversight of management.
Board’s
Role in Risk Oversight
While
risk management is primarily the responsibility of the Company’s
management team, the Board is responsible for the overall
supervision of the Company’s risk management activities. The Board
as a whole has responsibility for risk oversight, and each Board
committee has responsibility for reviewing certain risk areas and
reporting to the full Board. The oversight responsibility of the
Board and its committees is enabled by management reporting
processes that are designed to provide visibility to the Board
about the identification, assessment, and management of critical
risks and management’s risk mitigation strategies in certain focus
areas. These areas of focus include strategic, operational,
financial and reporting, succession and compensation and other
areas.
The
Board and its committees oversee risks associated with their
respective areas of responsibility. The full Board oversees: (i)
risks and exposures associated with our business strategy and other
current matters that may present material risk to our financial
performance, operations, prospects or reputation, (ii) risks and
exposures associated with management succession planning and
executive compensation programs and arrangements, including equity
incentive plans, and (iii) risks and exposures associated with
director succession planning, corporate governance, and overall
board effectiveness. The Audit Committee oversees overall policies
with respect to risk assessment and risk management, material
pending legal proceedings involving the Company and other
contingent liabilities, any potential related party or conflict of
interest transactions, as well as other risks and exposures that
may have a material impact on our financial statements.
Management
provides regular updates to the Board regarding the management of
the risks they oversee at each regular meeting of the Board. We
believe that the Board’s role in risk oversight must be evaluated
on a case-by-case basis and that our existing Board’s role in risk
oversight is appropriate. However, we continually re-examine the
manners in which the Board administers its oversight function on an
ongoing basis to ensure that they continue to meet the Company’s
needs.
Section
16(a) Beneficial Ownership Reporting Compliance
Section
16(a) of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”) requires our executive officers, directors and
persons who beneficially own more than 10% of our common stock to
file initial reports of ownership and reports of changes in
ownership with the SEC. Such persons are required by SEC
regulations to furnish us with copies of all Section 16(a) reports
filed by such persons.
Based
solely on our review of the copies of such reports furnished to us,
we believe that during the fiscal year ended December 31, 2019, all
executive officers, directors and greater than 10% beneficial
owners of our common stock complied with the reporting requirements
of Section 16(a) of the Exchange Act.
Executive
Officers
Executive
officers are appointed by our Board and serve at its discretion.
Set forth below is information regarding our executive officers as
of March 23, 2020.
Name |
|
Age |
|
Positions |
Anthony
K. McDonald* |
|
61 |
|
Chief
Executive Officer and President; Director |
|
|
|
|
|
* Mr.
McDonald currently also serves as our Principal Financial and
Accounting Officer. |
Mr.
McDonald’s biographical information is included with such
information for the other members of our Board.
We
have adopted a code of business conduct and ethics that applies to
our directors, officers and employees. The code of business conduct
and ethics is available on our website at www.surna.com. We
will report any amendments to or waivers of a required provision of
the code of business conduct and ethics on our website or in a Form
8-K.
Item 11. Executive
Compensation
Director
Compensation Program
On
January 2, 2020, the Board approved a revised compensation plan for
independent directors. Under this plan, the Company pays its
independent directors an annual cash fee of $30,000, payable
quarterly in advance, covering attendance at all regular or special
meetings of the Board or any committee thereof (including
telephonic meetings) and any other services provided by them as a
director (other than services as the Chairman of the Board and lead
independent director and the Chairman of the Audit
Committee).
The
Company pays the Chairman of the Board and lead independent
director an additional annual fee of $15,000, payable in cash
quarterly in advance. Mr. Keating is currently the Chairman of the
Board and is presently designated as the lead independent
director.
The
Company pays the Audit Committee Chairman, currently Mr. Simonton,
an additional annual fee of $15,000, payable in cash quarterly in
advance, for his services as the Audit Committee Chairman. There is
no additional compensation paid to members of the Audit
Committee.
For
independent directors elected or appointed on or after January 1,
2020, at the time of initial election or appointment, such
independent director will receive an equity award consisting of a
grant of non-qualified stock options to purchase 500,000 shares of
the Company’s common stock. The options will vest 50% upon grant
and 50% on the first anniversary of the grant date, have a term of
10 years, and have an exercise price equal to the closing price of
the Company’s common stock on the OTCMarkets on the day immediately
preceding the grant date.
In
addition, on the first business day of January each year, each
independent director will receive a grant of non-qualified stock
options to purchase 250,000 shares of the Company’s common stock,
which options will be immediately vested on the date of grant, have
a term of 10 years, and have an exercise price equal to the closing
price of the Company’s common stock on the OTCMarkets on the day
immediately preceding the grant date. In the case of a mid-year
election or appointment, the 250,000 options will be pro-rated for
each full quarter of service in the year of appointment. For
example, a new independent director appointed on April
15th of a particular year would serve two full quarters
of service in the remainder of that year (Q3 and Q4) and would
therefore be granted 125,000 options for the year of appointment
(50% of the award).
For
each of the two independent directors serving on January 1, 2020,
Messrs. Keating and Simonton, the Board also approved a special
one-time grant of non-qualified stock options to purchase 2,000,000
shares of the Company’s common stock, in recognition of the prior
services of each such independent director. These non-qualified
stock options were granted January 2, 2020, were immediately vested
on the date of grant, had a term of 10 years, and had an exercise
price of $0.07 per share, the closing price of the Company’s common
stock on the OTCMarkets on the day immediately preceding the grant
date.
Each
independent director is responsible for the payment of any and all
income taxes arising with respect to the issuance of any equity
awarded under the plan, including the exercise of any non-qualified
stock options.
The
Company also reimburses independent directors for out-of-pocket
expenses incurred in attending Board and committee meetings and
undertaking certain matters on the Company’s behalf.
Employee
directors do not receive separate fees for their services as
directors.
Under
the Nevada Revised Statutes and pursuant to our charter and bylaws,
as currently in effect, the Company may indemnify the Company’s
officers and directors for various expenses and damages resulting
from their acting in these capacities. Insofar as indemnification
for liabilities arising under the Securities Act may be permitted
to our officers and directors pursuant to the foregoing provisions,
we have been informed that, in the opinion of the SEC, this
indemnification is against public policy as expressed in the
Securities Act, and is therefore unenforceable.
The
Company has entered into indemnification agreements with its
directors and executive officers. The indemnification agreements
are intended to provide the Company’s directors the maximum
indemnification permitted under the Nevada Revised Statutes, unless
otherwise limited by the Company’s charter and bylaws. Each
indemnification agreement provides that the Company shall indemnify
the director or executive officer who is a party to the agreement
(an “Indemnitee”), including the advancement of legal expenses, if,
by reason of his corporate status, the Indemnitee is, or is
threatened to be, made a party to or a witness in any threatened,
pending, or completed proceeding. Each indemnification agreement
further provides that the applicable provisions of the Company’s
charter and bylaws regarding indemnification shall control in the
event of any conflict with any provisions of such indemnification
agreements.
Director
Compensation Table
The
following table sets forth the compensation earned by or awarded or
paid in 2019 to the individuals who served as our independent
directors during such period.
Name |
|
Fees
Earned
or
Paid in
Cash
(1)
|
|
|
Stock
Awards
(2)
|
|
|
Option
Awards (2), (3) |
|
|
Total |
|
Timothy J.
Keating |
|
$ |
45,000 |
|
|
$ |
30,000 |
|
|
$ |
117,063 |
|
|
$ |
192,063 |
|
J. Taylor
Simonton |
|
$ |
45,000 |
|
|
$ |
30,000 |
|
|
$ |
117,063 |
|
|
$ |
192,063 |
|
(1)
Excludes reimbursement of out-of-pocket expenses.
(2)
Reflects the dollar amount of the grant date fair value of awards,
measured in accordance with FASB Accounting Standards Codification
(“ASC”) Topic 718 (“Topic 718”) without adjustment for estimated
forfeitures. For a discussion of the assumptions used to calculate
the value of equity awards, refer to Note 14 to our consolidated
financial statements for the fiscal year ended December 31, 2019
included in this Annual Report.
(3)
Reflects special one-time grant to each independent director on
Janaury 2, 2020 of non-qualified stock options to purchase
2,000,000 shares of the Company’s common stock, in recognition of
the prior services of each such independent director.
The
aggregate number of non-qualified stock options held as of December
31, 2019 by each independent director are as follows:
Name |
|
Shares
Underlying
Non-Qualified
Stock
Options (1)
|
|
|
Shares
Underlying
Restricted
Stock
Units
|
|
|
Total |
|
Timothy J.
Keating |
|
|
2,000,000 |
|
|
|
– |
|
|
|
2,000,000 |
|
J. Taylor
Simonton |
|
|
2,900,000 |
|
|
|
– |
|
|
|
2,900,000 |
|
(1)
Includes special one-time grant to each independent director on
Janaury 2, 2020 of non-qualified stock options to purchase
2,000,000 shares of the Company’s common stock, in recognition of
the prior services of each such independent director.
Executive
Compensation Philosophy and Objectives
The
Company has not established a compensation committee. Accordingly,
the Board is responsible for setting compensation policies for
executive officers which has two fundamental objectives: (i) to
provide a competitive total compensation package that enables the
Company to attract and retain highly qualified executives with the
skills and experience required for the achievement of business
goals; and (ii) to align certain compensation elements with the
Company’s annual performance goals. The Board considers, with
respect to each of the Company’s executive officers, the total
compensation that may be awarded, including base salary,
discretionary cash bonuses, annual stock incentive awards, stock
options, restricted stock units and other equity awards, and other
benefits and perquisites. Under certain circumstances, the Board
may also award compensation payable upon termination of the
executive officer under an employment agreement or severance
agreement (if applicable). The Board recognizes that its overall
goal is to award compensation that is reasonable when all elements
of potential compensation are considered. The Board believes that
cash compensation in the form of base salary and discretionary cash
bonuses provides our executives with short-term rewards for success
in operations, and that long-term compensation through the award of
stock options, restricted stock units and other equity awards
aligns the objectives of management with those of our stockholders
with respect to long-term performance and success.
The
Board also has historically focused on the Company’s financial
condition when making compensation decisions and approving
performance objectives. Because the Company has historically sought
to preserve cash and currently does not operate at a profit,
overall compensation traditionally has been weighted more heavily
toward equity-based compensation. The Board will continue to
periodically reassess the appropriate weighting of cash and equity
compensation in light of the Company’s expenditures in connection
with commercial operations and its cash resources and working
capital needs.
Summary
Executive Compensation Table
The
following table summarizes compensation earned by or awarded or
paid to our named executive officers for the years ended December
31, 2019 and 2018.
Name
and Principal Position |
|
Year |
|
|
Salary |
|
|
Bonus |
|
|
Stock
Awards (1) |
|
|
Option
Awards (1) |
|
|
Non-equity
Incentive Plan Compensation |
|
|
Non-qualified
Deferred Compensation Earnings |
|
|
All
Other Compensation |
|
|
Total |
|
Anthony
K. McDonald - |
|
2019 |
|
|
$ |
180,000 |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
58,532 |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
13,900 |
|
|
$ |
252,432 |
|
Chief
Executive Officer and President (2) |
|
|
2018 |
|
|
$ |
13,154 |
|
|
$ |
- |
|
|
$ |
30,000 |
|
|
$ |
373,836 |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
9,398 |
|
|
$ |
426,388 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Brandy
M. Keen |
|
|
2019 |
|
|
$ |
183,726 |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
14,320 |
|
|
$ |
198,046 |
|
(former
Vice President and Secretary) (3) |
|
|
2018 |
|
|
$ |
174,656 |
|
|
$ |
- |
|
|
$ |
883,200 |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
10,448 |
|
|
$ |
1,068,304 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chris
Bechtel |
|
|
2019 |
|
|
$ |
7,561 |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
7,561 |
|
(former
Chief Executive Officer and President) (4) |
|
|
2018 |
|
|
$ |
180,000 |
|
|
$ |
125,000 |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
20,608 |
|
|
$ |
325,608 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Mark
E. Smiens |
|
|
2019 |
|
|
$ |
18,454 |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
18,454 |
|
(former
Chief Financial Officer, Treasurer and Secretary)
(5) |
|
|
2018 |
|
|
$ |
71,346 |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
3,342 |
|
|
$ |
74,688 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aaron
Trent Doucet |
|
|
2019 |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
(former
Chief Executive Officer) (6) |
|
|
2018 |
|
|
$ |
40,938 |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
34,531 |
|
|
$ |
75,469 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Paul
C. Kelly |
|
|
2019 |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
(former
Chief Financial Officer and Treasurer) (7) |
|
|
2018 |
|
|
$ |
35,102 |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
35,102 |
|
(1)
Reflects the dollar amount of the grant date fair value of awards
granted in 2018 or 2019, measured in accordance with FASB
Accounting Standards Codification (“ASC”) Topic 718 (“Topic 718”)
without adjustment for estimated forfeitures. For a discussion of
the assumptions used to calculate the value of equity awards, refer
to Note 14 to our consolidated financial statements for the fiscal
year ended December 31, 2019 included in this Annual
Report.
(2)
Mr. McDonald was appointed Chief Executive Officer and President in
November 2018. Amounts presented include all compensation for Mr.
McDonald for the full 2018 and 2019 years. Stock awards include
restricted stock units awarded in September 2018 as an equity
retainer fee in connection with his appointment as an independent
directror in September 2018, net of the restricted stock units
cancelled when Mr. McDonald was apopinted Chief Executive Officer
and President. Option awards represent: (i) non-qualified stock
options to purchase 5,000,000 shares of common stock awarded in
November 2018, and (ii) non-qualified stock options to purchase
1,000,000 shares of common stock awarded in January 2020, based on
our 2019 performance and Mr. McDonald’s contributions to such
performance, some of which options are subject to certain to
vesting (see Outstanding Equity Awards table, below). Other
compensation in 2018 and 2019 includes employer-paid portion of
health plan benefits ($349 and $6,700, respectively), and (ii)
employer matching contributions under our 401(k) plan ($0 and
$7,200, respectively). Other compensation for 2018 also includes
cash fees earned or paid in his capacity as an independent director
prior to his appointment as CEO ($9,049).
(3)
Ms. Keen was Vice President and Secretary from July 2017 until her
resignation in May 2018. Amounts presented include all compensation
for Ms. Keen for the full 2018 and 2019 years. Salary includes
sales incentive compensation. Stock awards represent restricted
stock units awarded in 2018 which are subject to vesting (see
Outstanding Equity Awards table, below). Other compensation for
2018 and 2019 includes employer matching contributions under our
401(k) plan ($6,382 and $7,349, respectively) and employer-paid
portion of health plan benefits ($4,066 and $6,971,
respectively).
(4)
Mr. Bechtel was Chief Executive Officer and President from August
2017 until his resignation in November 2018. Amounts presented
include all compensation for Mr. Bechtel for the full 2018 and 2019
years. Bonus represents incentive stock bonus earned in 2018 per
his employment agreement. Other compensation for 2018 includes
employer-paid portion of health plan benefits ($4,850). Other
compensation for 2018 also includes $15,758 for the gross-up on
certain withholding taxes paid by us related to equity
awards.
(5)
Mr. Smiens was Chief Financial Officer and Treasurer from July
2018, and Secretary from September 2018, until his termination of
employment in December 2018. Amounts presented include all
compensation for Mr. Smiens for the full 2018 and 2019 year. Other
compensation for 2018 includes employer matching contributions
under our 401(k) plan ($1,616) and employer-paid portion of health
plan benefits ($1,726).
(6)
Mr. Doucet served as President and Chief Executive Officer from
June 2016 until his resignation in August 2017. From August 2017
until March 2018, Mr. Doucet served as our Vice President of
Business Development. Amounts presented include all compensation
for Mr. Doucet for the full 2018 and 2019 years. Salary includes
sales incentive compensation. Other compensation for 2018 includes
a car allowance ($3,323) and the gross-up on certain withholding
taxes paid by us related to equity awards ($31,208).
(7)
Mr. Kelly was Chief Financial Officer and Treasurer from August
2017 until his resignation in January 2018.
Outstanding
Equity Awards
The
following table sets forth certain information regarding
outstanding equity awards held by our named executive officers as
of December 31, 2019.
|
|
Option
Awards |
|
|
Stock
Awards |
|
Name |
|
Number of
Securities Underlying Unexercised Options Exercisable |
|
|
Number of
Securities Underlying Unexercised Options Unexercisable |
|
|
Equity
Incentive Plan Awards: Number of Securities Underlying Unexercised
Unearned Options |
|
|
Option
Exercise Price |
|
|
Option
Expiration Date |
|
|
Number of
Shares or Units of Stock That Have Not Vested |
|
|
Market
Value of Shares or Units of Stock That Have Not Vested
(1) |
|
|
Equity
Incentive Plan Awards: Number of Unearned Shares, Units or Other
Rights That Have Not Vested |
|
|
Equity
Incentive Plan Awards: Market or Payout Value of Unearned Shares,
Units or Other Rights That Have Not Vested
(1) |
|
Anthony
K. McDonald (2) |
|
|
3,000,000 |
|
|
|
– |
|
|
|
2,000,000 |
|
|
$ |
0.089 |
|
|
|
11/28/2028 |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
|
1,000,000 |
|
|
|
– |
|
|
|
– |
|
|
$ |
0.070 |
|
|
|
1/2/2030 |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Brandy
M. Keen (3) |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
800,000 |
|
|
$ |
56,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chris
Bechtel |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Mark E.
Smiens |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aaron
Trent Doucet (4) |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Paul C.
Kelly |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
(1)
Calculated by multiplying the number of unvested shares or units by
$0.07, the closing price per share of our common stock as reported
by the OTCQB on December 31, 2019.
(2)
On November 28, 2018, we granted to Mr. McDonald non-qualified
stock options to purchase 5,000,000 shares of common stock under
our 2017 Equity Incentive Plan, of which: (i) 1,000,000 options
vested and became exercisable on the grant date, (ii) 2,000,000
options vested and became exercisable on December 31, 2019, and
(iii) 2,000,000 options will vest and become exercisable on
December 31, 2020, if he continues to be employed by us on that
date. On Janaury 2, 2020, we granted to Mr. McDonald non-qualified
stock options to purchase 1,000,000 shares of common stock under
our 2017 Equity Incentive Plan in recognition of his performance
during 2019, which options vested and became exercisable on the
grant date.
(3)
On May 29, 2018, we granted to Ms. Keen 4,800,000 restricted stock
units under our 2017 Equity Incentive Plan which, as of December
31, 2019: (i) we have issued 32,000,000 shares of common stock in
settlement of vested restricted stock units, (ii) 1,000,000 shares
of common stock in settlement of restricted stock units that vested
December 31, 2019 were issued subsequent to December 31, 2019,
(iii) the parties mutually agreed to cancel 1,000,000 restricted
stock units, and (iii) 800,000 restricted stock units are scheduled
to vest on April 30, 2020, subject to her continued employment
through the vesting date.
(4)
On August 17, 2017, we granted to Mr. Doucet 9,000,000 restricted
stock units, which vested in 12 equal installments (750,000 units
per installment) commencing on the first business day of January
2018 and continuing on the first business day of each of the next
11 calendar months. As of December 31, 2019, we issued 2,250,000
shares of common stock in settlement of certain vested restricted
stock units. The remaining 6,750,000 vested restricted stock units
were not settled with the issuance of shares until March 9, 2020
due to a dispute with a former employee over the required
withholding taxes to be paid to the Company for remittance to the
appropriate tax authorities.
Compensation
Arrangements with Named Executive Officers
The
following summarizes the employment agreement that the Company has
entered into with Mr. McDonald, as of December 31, 2019.
Anthony K. McDonald
On
November 28, 2018, the Company entered into an employment agreement
with Mr. McDonald, the Company’s Chief Executive Officer and
President. The initial term of the employment agreement commenced
on November 28, 2018 and will continue until December 31, 2020.
However, the Company and Mr. McDonald may terminate the employment
agreement, at any time, with or without cause, by providing the
other party with 30-days’ prior written notice. In the event Mr.
McDonald’s employment is terminated by the Company during the
initial term without cause, Mr. McDonald will be entitled to
receive his base salary for an additional 30 days. Following the
initial term, the Company and Mr. McDonald may extend the
employment agreement for additional one-year terms by mutual
written agreement. Under the employment agreement, Mr. McDonald
received in 2019 an annualized base salary of $180,000. Effective
January 1, 2020, the annualized base salary was increased to
$200,000.
Under
the employment agreement, the Board approved an award of
non-qualified stock options to purchase 5,000,000 shares of the
Company’s common stock under the Company’s 2017 Equity Incentive
Plan, as may be modified and amended by the Company from time to
time (the “2017 Equity Plan”), which vest as follows: (i) 1,000,000
options vested and became exercisable on November 28, 2018, the
grant date, (ii) 2,000,000 options vested and became exercisable on
December 31, 2019, and (iii) 2,000,000 options vest and become
exercisable on December 31, 2020, if Mr. McDonald continues to be
employed by the Company on that date. The exercise price of these
options is $0.089, based on the closing of the Company’s common
stock on November 27, 2018. In the event of a change of control
involving the Company, any non-qualified stock options not already
vested will become vested, provided Mr. McDonald continues to
provide services to the Company on the date immediately preceding
the date of the change of control.
In
consideration of the grant of the above non-qualified stock
options, Mr. McDonald agreed to cancel 197,368 RSUs, which were
granted to him as an equity retention award in connection with Mr.
McDonald’s appointment to the Board on September 12, 2018 and which
had not vested as of November 28, 2018.
On
January 2, 2020, the Board also awarded Mr. McDonald a special
one-time grant of non-qualified stock options to purchase 1,000,000
shares of the Company’s common stock, in recognition of his
services as the Company’s Chief Executive Officer during 2019.
These non-qualified stock options were immediately vested on the
date of grant, had a term of 10 years, and had an exercise price of
$0.07 per share, the closing price of the Company’s common stock on
the OTCMarkets on the day immediately preceding the grant
date.
Item 12. Security Ownership of Certain
Beneficial Owners and Management and Related Stockholder
Matters
The
following table sets forth the shares of our common stock
beneficially owned by (i) each of our directors, (ii) each of our
named executive officers, (iii) all of our directors and executive
officers as a group, and (iv) all persons known by us to
beneficially own more than 5% of our outstanding common stock. The
Company has determined the beneficial ownership shown on this table
in accordance with the rules of the SEC. Under these rules, shares
are considered beneficially owned if held by the person indicated,
or if such person, directly or indirectly, through any contract,
arrangement, understanding, relationship or otherwise, has or
shares the power to vote, to direct the voting of and/or to dispose
of or to direct the disposition of such shares. A person is also
deemed to be a beneficial owner of shares if that person has the
right to acquire such shares within 60 days through the exercise of
any warrant, option or right or through conversion of a security.
Except as otherwise indicated in the accompanying footnotes, the
information in the table below is based on information as of March
23, 2020. Unless otherwise indicated in the footnotes to the
following table, each person named in the table has sole voting and
investment power with respect to shares of common and preferred
stock and the address for such person is c/o Surna Inc. 1780 55th
Street, Boulder, Colorado 80301.
|
|
Common
Stock |
|
|
Preferred
Stock |
|
Name of
Beneficial Owner |
|
Number
of Shares Owned Beneficially (1) |
|
|
Percentage
of Class (2) |
|
|
Number
of Shares Owned Beneficially (1) |
|
|
Percentage
of Class (3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Directors |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Anthony
K. McDonald (4) |
|
|
4,197,368 |
|
|
|
1.7 |
% |
|
|
- |
|
|
|
- |
|
Timothy
J. Keating(5) |
|
|
4,442,672 |
|
|
|
1.9 |
% |
|
|
- |
|
|
|
- |
|
J.
Taylor Simonton (6) |
|
|
3,887,116 |
|
|
|
1.6 |
% |
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Executive
Officers who are not Directors |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Executive
Officers and Directors as a Group |
|
|
12,527,156 |
|
|
|
5.1 |
% |
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5% or More
Stockholders |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Brandy
M. Keen (7) |
|
|
17,766,308 |
|
|
|
7.5 |
% |
|
|
- |
|
|
|
- |
|
Morgan
Paxhia (8) |
|
|
- |
|
|
|
- |
|
|
|
33,428,023 |
|
|
|
79.5 |
% |
Chris
Bechtel (9) |
|
|
14,543,366 |
|
|
|
6.1 |
% |
|
|
- |
|
|
|
- |
|
John
F. Jansen (10) |
|
|
16,213,366 |
|
|
|
6.7 |
% |
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
Beneficial ownership has been determined in accordance with Rule
13d-3 under the Exchange Act.
(2)
Based on a total of 236,526,638 shares of the Company’s common
stock issued and outstanding as of March 23, 2020.
(3)
Based on a total of 42,030,331 shares of the Company’s preferred
stock issued and outstanding as of March 23, 2020. The holders of
preferred stock vote as a separate class on matters affecting the
preferred stock.
(4)
Includes 4,000,000 shares of common stock issuable upon the
exercise of options exercisable within 60 days.
(5)
Includes 2,250,000 shares of common stock issuable upon the
exercise of options exercisable within 60 days.
(6)
Includes 3,150,000 shares of common stock issuable upon the
exercise of options exercisable within 60 days.
(7)
Beneficial ownership based on share ownership reported by Ms. Keen
to the Company as of March 6, 2020. Includes shares of common stock
held jointly with her spouse, Stephen B. Keen. Includes 800,000
shares of common stock issuable upon settlement of restricted stock
units which vest within 60 days.
(8)
Includes 33,428,023 shares of preferred stock owned by Demeter
Capital Group LP (“Demeter”). Mr. Paxhia and his sister, Emily
Paxhia, are the managing members of Poseidon Asset Management, LLC
(“Poseidon”), which is the general partner and/or investment
manager of Demeter and in such capacity exercises voting and
dispositive power over the securities beneficially owned by
Demeter. The address for Mr. Paxhia, Ms. Paxhia, Poseidon and
Demeter is 130 Frederick Street, #102, San Francisco, CA
94117.
(9)
Beneficial ownership based on share ownership reported by Mr.
Bechtel to the Company as of March 9, 2020. Includes shares held in
entities or accounts over which Mr. Bechtel and/or his spouse have
beneficial ownership or exercise voting control. Includes 1,631,250
shares of common stock issuable upon the exercise of warrants
exercisable within 60 days. The address for Mr. Bechtel is 31 Cape
Harbour Place, The Woodlands, TX 77380.
(10)
Beneficial ownership based on Schedule 13G dated May 25, 2018 filed
by Mr. Jansen with the SEC, and share ownerhsip reported by Mr.
Jansen to the Company as of February 27, 2020. Includes 4,200,000
shares of common stock issuable upon the exercise of warrants
exercisable within 60 days. The address for Mr. Jansen is 4910
Kaylan Court, Richmond, TX 77407.
Item 13. Certain Relationships and
Related Transactions, and Director Independence
Transactions
with Related Parties
The
following describes certain agreements and transactions between the
Company and its co-founders, Brandy and Stephen Keen (the
“Co-founders”). The Co-founders held various executive officer and
director positions with the Company until May 2018. One of the
Co-founders also was a consultant to the Company until May 2018.
The Co-founders are also shareholders of the Company. Based on
information available to the Company, the Co-founders did not own
more than 10% of the Company’s outstanding common stock at any time
during 2019.
Consulting Agreement. In May 2017, we entered into a
three-year consulting agreement with Mr. Keen to provide certain
consulting services to us, including research and development, new
product design and innovations, existing product enhancements and
improvements, and other technology advancements with respect to our
business and products in exchange for an annual consulting fee of
$30,000. In May 2018, the consulting agreement was terminated by
the parties.
Equipment, Demonstration and Product Testing
Agreement. In May 2017, we entered into a three-year
equipment, demonstration and product testing agreement with a
licensed cannabis cultivation company affiliated with Mr. Keen.
Under this agreement, we agreed to lease the cultivation company
certain cultivation equipment in exchange for a quarterly fee of
$16,500, which was increased to $18,330 to reflect additional
leased equipment requested by the cultivation company (the “Lease
Fee”). In consideration for access to the cultivation facility to
conduct demonstration tours and for the product testing and data to
be provided by the cultivation company, we agreed to pay the
cultivation company a quarterly fee of $12,000 (the “Demo and
Testing Fee”).
The
parties each made their respective payments under this agreement
through June 30, 2018. Thereafter, the cultivation company failed
to make any subsequent payments of the Lease Fee and, as a result,
the Company did not pay the Demo and Testing Fee. During the second
quarter of 2019, we notified the cultivation company of its breach
for non-payment of the Lease Fee. In February 2020, the parties
mutually agreed to terminate this agreement and release each other
from all claims related to this agreement, including any unpaid
Lease Fees or Demo and Testing Fees. We also agreed to transfer the
equipment to the cultivation company for no additional
consideration.
Employment Agreement. In May 2018, we entered into
an employment agreement with Ms. Keen, which provided for an
initial base salary of $150,000 per year and certain sales
incentive. Pursuant to the employment agreement, we awarded
4,800,000 restricted stock units (“RSUs”) to Ms. Keen that vested
at certain dates in the future, subject to her continued
employment.
Stock Repurchase Agreement. In May 2018, we entered
into a stock repurchase agreement with the Keens, pursuant to which
we agreed to repurchase from them certain shares of our common
stock, subject to the closing of a private placement offering to
accredited investors, which occurred during the second quarter of
2018. In June 2018, we closed the transaction under the stock
repurchase agreement and repurchased 3,125,000 shares of our common
stock from the Keens for a total purchase price of
$400,000.
Purchase of Preferred Stock. In May 2018, we entered
into a preferred stock option agreement with the Keens, under which
we had the right, but not the obligation, to acquire all 35,189,669
shares of preferred stock owned by the Keens (the “Preferred
Stock”) on or before April 30, 2020. Pursuant to the preferred
stock option agreement, upon our exercise of the option, we agreed
to issue one share of our common stock for each 1,000 shares of
Preferred Stock purchased by us. As consideration for the Keens’
grant of the option, we paid them $5,000. We exercised this option
and, in December 2018, completed the repurchase by the Preferred
Stock and issued 35,190 shares of our common stock to the
Keens.
***************
During
2019, except as discussed above, there have been no transactions in
which the Company was or is a participant, and there are no
currently proposed transactions in which the Company is to be a
participant, in which the amount involved exceeds the lesser of
$120,000 or 1% of the Company’s average assets at year-end for the
last two completed fiscal years, and in which any director,
executive officer or beneficial holder of more than 5% of any class
of our voting securities or member of such person’s immediate
family had or will have a direct or indirect material
interest.
Company
Policy Regarding Related Party Transactions
The
Company has procedures in place for the review, approval and
monitoring of transactions involving the Company and certain
persons related to the Company. For example, the Company has a code
of business conduct and ethics that generally prohibits any
employee, officer or director from engaging in any transaction
where there is a conflict between such individual’s personal
interest and the interests of the Company. Waivers to the code of
business conduct and ethics can generally only be obtained from the
Board and are publicly disclosed as required by applicable law and
regulations.
In
addition, the charter of the Audit Committee of our Board tasks the
Audit Committee with reviewing all related party transactions for
potential conflict of interest situations on an ongoing basis (if
such transactions are not reviewed and overseen by another
independent body of the Board). In accordance with that policy, the
Audit Committee’s general practice is to review and oversee any
transactions that are reportable as related party transactions
under the Financial Accounting Standards Board (“FASB”) and SEC
rules and regulations. Management advises the Audit Committee and
the full Board on a regular basis of any such transaction that is
proposed to be entered into or continued and seeks
approval.
Item 14. Principal Accountant Fees and
Services
ACM
LLP (“ACM”) has acted as the Company’s independent registered
public accounting firm for the fiscal years ended December 31, 2019
and 2018. ACM has advised us that neither the firm nor any present
member or associate of it has any material financial interest,
direct or indirect, in the Company or its affiliates.
The
following table summarizes the fees of ACM for the years ended
December 31, 2019 and 2018, respectively:
|
|
2019 |
|
|
2018 |
|
Audit
Fees |
|
$ |
135,000 |
|
|
$ |
135,000 |
|
Audit-Related
Fees |
|
|
- |
|
|
|
- |
|
Tax
Fees |
|
|
16,960 |
(1) |
|
|
19,500 |
(2) |
Other
Fees |
|
|
- |
|
|
|
- |
|
Total |
|
$ |
151,960 |
|
|
$ |
154,500 |
|
|
(1) |
Tax fees
in 2019 relate to tax returns for the 2018 year |
|
(2) |
Tax fees
in 2018 relate to tax returns for the 2017 year |
Audit
Fees. Audit fees consist of fees billed by our independent
registered public accounting firms for professional services
rendered in connection with the audit of our annual consolidated
financial statements, and the review of our consolidated financial
statements included in our quarterly reports.
Audit-Related
Fees. Audit-related services consist of fees billed by our
independent registered public accounting firms for assurance and
related services that are reasonably related to the performance of
the audit or review of the Company’s financial statements and are
not reported under “Audit Fees.” These services include the review
of our registration statements on Forms S-8.
Tax
Fees. Tax fees consist of fees billed by our independent
registered public accounting firms for professional services
rendered for tax compliance, tax planning and tax advice. These
services include assistance regarding federal, state, and local tax
compliance.
All
Other Fees. All other fees would include fees for products and
services other than the services reported above.
Pre-Approval
Policy
Our
Audit Committee pre-approves all services to be provided by our
independent registered public accounting firm. Since the formation
of our Audit Committee in May 2017, all fees paid to our
independent registered public accounting firm for services were
pre-approved by our Audit Committee.
PART IV
Item 15. Exhibits and Financial Statement
Schedules
a.
Documents Filed as Part of this Report
The
following consolidated financial statements of Surna Inc. are filed
as part of this Annual Report on Form 10-K: